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Commentaries
Being “Normal”
  In  certain  areas  it  is  easy  to 
define  “normal.”  In  other  areas  it  is 
challenging or impossible.  In general, 
if given a choice, we prefer normality 
although we  sometimes  like  to  stand 
out.  For things that can be measured 
we  can  define  normal,  assuming 
that  the measurement  has  a  “normal 





more  musical,  more  artistic,  more 
clever,  nicer,  more  successful,  etc. 
These are “normal” desires.  
  We  can’t  define  normal 
appearance,  nor  can  we  define 
normal  behavior.    We  know  what 
seems  “freakish”  in  appearance  and 
we  have  a  fairly  uniform  agreement 
on what behaviors are clearly beyond 
the  normal,  and  probably  to  a 
lesser  extent,  an  agreement  on  what 
behaviors  are  considered  “abnormal.” 
In  non-statistical  terms,  we  might 
consider some behaviors to be “fringe” 
behaviors,  borderline  acceptable, 
perhaps  eccentric  and  “different”  but 
not clearly “abnormal.”
  Almost all of us have dreaded “not 
fitting  in.”    We  are  an  impressively 
conforming  species.    Dress  codes, 
work habits, gender stereotypes, social 
intercourse  are  quite  strictly  defined 
in  the  various  cultures  of  the  world 
and  deviation  is  not  generally  well 
accepted.
  It  is  this  fairly  straightforward 
and banal view of the world, which I 
think is shared by most people, that is 
challenged in a recent book, One of Us. 
The  author,  a  non-physician,  reports 
on the world of Siamese twins.   Her 
thesis is that Siamese twins, sharing a 
world  so  close, have  a  life  experience 
that is so closely shared that no one else 
can possibly  imagine  it.   This  shared 
life  is  so  special  and  wonderful  that 
it  overcomes  the  obvious  difficulties 
that  having  a  shared  body  requires. 
A point stated repeatedly, that only a 
single  set of Siamese  twins who were 
adults  ever  decided  to  undergo  a 
surgical separation.  This observation, 
the  author  suggests,  indicates  that 
Siamese  twin  adults  prefer  their  life, 
see  themselves  as  quite  special,  and 








with  cleft  palate  repair,  more  social 
behavior supports have been provided 
to the children and their families, and 
that  some  people  who  did  not  have 
this surgery are glad that they didn’t.
  I read the review of this book in the 
New England Journal of Medicine and 
bought it right away.  I love iconoclastic 
thinking.    I  love  to  be  intellectually 
provoked, to have to rethink my basic 
assumptions on almost anything.  One 
either  strengthens  old  convictions  by 





son,  purporting  to  show  that  1=2. 
The  various  steps  in  the  proof  are 
self-evident, starting with the “given,” 
that  a=b,  then  progressing  through 
a  few  simple  arithmetic  steps,  the 
penultimate one being division by  a-
b.  Unfortunately a-b=0, and division 
by  zero  is  not  allowed.    The  proof 
that 1=2 founders on an unacceptable 
step.    The  book  above  lacks  what 
psychologists  call  “face  validity.” 
Asking  Siamese twins whether they’d 
prefer  to  be  separate  is  almost  akin 
to  asking  someone  if  they’d  rather 
never  have  been  born.    It  is  almost 
unthinkable,  I  suspect,  to  imagine  a 
life  so  totally  different  than  the  one 
you’d  led,  to  imagine  two  points  of 
view when you’ve always had one,  to 
imagine  a  freedom  unimaginable,  to 
live “on your own” once you’re an adult 
who  never  had  such  an  opportunity. 
The book makes clear that one of the 
largest  preoccupations  of  the  general 
public is how these twins have sexual 
relations  (some have had  families)  or 
even toilet themselves.
  On  National  Public  Radio 
several years ago I heard a program on 
dwarfism  and  abortion.    The  world 
of  the  achondroplastic  dwarf,  the 
most  common  form  of  dwarfism,  is, 
as one would imagine, quite different 
than  the  world  of  larger,  “normal” 
people.    The  issue  being  considered 
was  the  ethics  of  an  achondroplastic 
couple  having  an  abortion  if  the 
fetus was normal  and not affected by 
dwarfism,  since  it  was  reported  that 
achondroplastic  dwarf  couples  prefer 
to  have  children  like  themselves.    I 
have no idea if other groups of people 
with  genetic  disorders,  for  example, 
people  with  inherited  deafness,  feel 
the  same  way.  Perhaps  this  could  be 
true for Siamese twins.  I suspect that 
most  people,  especially  doctors,  who 
routinely  interact  with  many  more 
people in much more intimate settings 
than  most  people,  would  find  the 
concept  of  Siamese  twins  refusing  to 
be separated as lacking “face validity.” 
Currently  the  operations  are  dictated 
by the parents, who, like most of us, see 
very little of value in maintaining the 
connection  between  the  two  bodies. 
“Normal” trumps “special,” especially 
when  “special”  does  not  look  in  any 
way appealing.  How can anyone argue 
that  the  surgery  should  await  adult 
decision-making,  when  the  surgery 
becomes  more  dangerous  AND  the 
personalities  become  increasingly 
formed by the unique circumstances? 
On  the  other  hand,  maybe  there’s  a 
power in two twins sharing a life. 
  Bipolar  (manic  depressive 
disorder)  disease  has  been  associated 
with  increased  creativity.    If  bipolar 
disease  could  be  “cured”  (not  simply 
controlled), but only in childhood, and 
this  resulted  in  diminished  creativity 
in adults, would we do it? And would 
it  matter  if  we  knew  the  child  was 
or was  not  destined  to  be  “creative?” 
“Curing” conjoined twins is now often 
possible.  Other life altering “cures” of 
non-fatal  disorders  and  anomalies  lie 
in the near future.  Ethical issues will 
undoubtedly abound.
Joseph H. Friedman, MD
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The Gaols that Spawn Disease
From bitter, intimate experience, Oscar Wilde once wrote:
I know not whether the laws be right,
Or whether laws be wrong;
All that we know who lie in Gaol
Is that the wall is strong.
  Wilde  had  been  imprisoned  in  Reading  Gaol  (in  the 
US,  spelled  jail)  from 1895 to 1897; and upon his  release  , 
he changed his name to Sebastian Melmoth, fled in haste to 
France,  and within years died an embittered,  lonely person. 





  Charles  Dickens  frequently  described  the  infamous 
prisons of London. Talking of the wretched Newgate Gaol:
  “But,  the gaol was a vile place  in which most kinds of 
debauchery  and  villainy  were  practiced,  and  where  dire 
diseases were bred,  that came  into court with  the prisoners, 
and  sometimes  rushed  straight  from  the  dock  at  my  Lord 
Chief Justice himself, and pulled him off the bench.  It had 
more  than  once  happened  that  the  judge  in  the  black  cap 
pronounced his own doom as certainly as the prisoner’s, and 
even died before him.”
  Dickens was  referring,  in general,  to  that “dire disease” 
known  as  gaol  fever  which  was  the  dreaded  pestilence 




disease  (since,  on  many  occasions,  it  had  decimated  the 
Holy Roman Empire armies during  their periodic  invasions 





  But  Dickens  was  referring  to  something more  specific 
than the disease which had killed far more soldiers than all the 
battlefield casualties caused by gunfire, and far more English 
prisoners  than  all  of  the  sanctioned  hangings  at  Newgate 
prison.
  The  year  was  1577  and  Queen  Elizabeth  was  in  the 
nineteenth year of her lengthy reign. The English realm was 
relatively  quiet,  the  threat  of  a  Spanish  armada  would  not 
materialize  for  another decade,  and while  smallpox,  syphilis 
and bubonic plaque continued  to be  endemic,  this had not 
been a year of notable epidemic intensity of any of these three 
pestilences.
  In  July  of  1577,  in Oxfordshire,  the periodic Assize  (a 
word of Latin origin meaning  an official  court  session) was 
convened  in  the Old County Hall on New Road. Presiding 
over the court was Sir Robert Bell, Lord Chief Baron of the 







caverns  beneath  the  courtroom,  where  about  three  hundred 
prisoners  were  closely  held  while  awaiting  their  summary 
judgments  issued  by  the  court  then  in  session.    Gaol  fever, 
with  its  terrible headaches, hectic  fevers, blotchy skin rashes, 
delirium and high mortality  rate had  spread  rapidly  through 
these  huddled  masses  of  prisoners.  And  within  forty  days, 






  By  the  18th  Century,  gaol  fever  became  a  known 
occupational  hazard  for  court  attendants  –even  judges.    As 
long  as  the  English  legal  system  required  that  prisoners  be 
afforded  a day  in  court,  facing  the  judge,  the hazard  existed 
of the prisoner’s  lice-infected body contaminating the judge’s 
robes.    And  so,  periodically,  English  magistrates  learned, 











for  intemperate  verbiage which his  trial  declared  to be  libel, 
have since become more tolerant. Prisons, at least in Western 
nations,  have  become  less  dungeons  and  more  impersonal 
lockups with  relatively  sanitary  facilities,   Typhus,  therefore, 




  An  eminent  physician-bacteriologist,  Hanz  Zinnser, 
wrote  a  book  on  the  history  of  typhus.   This  1934  classic, 
Rats, Lice and History, offered a comprehensive review of the 
tragic impact of typhus fever upon the many European armies, 
including Napoleon’s Grand Army in its ill-considered invasion 
of  Russia,  and  particularly  the  destructive  role  of  typhus  in 
devastating the trench-bound troops of World War I, especially 








 Stanley M. Aronson, MD
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Introduction: Women’s Health
This  edition  of  Medicine & Health/Rhode Island 
represents  a  partnership  between  the  rhode island 
department of health (health)  Office  of Women’s 
Health  and  the  Brown  University  /  Women  &  Infants 




The  HEALTH  Office  of  Women’s  Health  works 
to  elevate  the  health  status  of  women  and  girls  by 
coordinating internal  HEALTH efforts and collaborating 
statewide with agencies that advocate for women and girls. 
Since    being  designated  a    CoE  by  the US Department 
of  Health  and  Human  Services  in  2003,  the  mission 
of  the  Brown  University  /  Women  &  Infants  Hospital 
National  Center  of  Excellence  in  Women’s  Health  has 
been  to  foster  participation  and  contributions  from  the 
community  to  improve  health  and  health  care  for  all 
women.  This mission is accomplished through promoting 
representation of women from all backgrounds in medical 
leadership  positions,  enhancing  professional  education, 




HEALTH  and  the  CoE  to  improve  women’s  health  in 
Rhode Island, by educating practitioners about key clinical 
issues  facing  their women patients. Articles  focus  on  the 





and  where  clinical  trials  have  not  effectively  included 
women to establish appropriate treatment regimens. 
Dr.  Barbara  Roberts    in  “Gender  Specific  Aspects 
of  Cardiovascular  Disease”  points  out  that  women  with 




Moura  discusses irritable Bowel syndrome (iBs),  a 
complex  disorder of unknown cause and cure, which affects 
a  higher  proportion  of  women  than men.    She  outlines 
criteria  for  the  diagnosis  of    IBS  and  options  physicians 
can  take  to  alleviate  its  symptoms.    Understanding  that 
many  women  have  concerns  around  weight  gain  and 
incontinence,  especially  as  they  bear  children  or  become 
older,  two  articles  focus  on  these  issues.    Drs.  Suzanne 
Phelan  and  Rena  Wing  provide  recommendations  for 
the promotion of healthy lifestyles and weight control for 
women,  particularly  during  pregnancy  and  menopause. 
Drs. Vivian Sung and Deborah Myers review the economic 
impact of stress urinary incontinence (sUi) and advances 
in surgical options.
Many of the columns have a Women’s Health focus. 
“Images  in Medicine,”    by Drs.  Beth  Plante  and Troilus 
Plante,  illustrates  radiological  findings  in  a  woman  with 
abdominal  pain. Doctors  of  Pharmacy  Sarah G.  Kachur, 
Christine  L.  Hannan,  and  Kristina  E.  Ward  discuss 
“Antidepressant-Induced  Weight  Gain”  in  Advances  in 
Pharmacology,
Dr.  Jennifer Gass  describes  a  vision  of  the  future  of 
breast surgery in “Creative Clinician.”  Drs. Linsay Madom 
and Lori Boardman explain  the utility of HPV testing  in 
the  context  of  cervical  cancer  screening  in  Advances  in 
Laboratory Medicine.  Columnists  from  Quality  Partners 
of RI and the Rhode Island Department of Health focus on 
women’s health.  
In  summary,  this  edition  brings  together  clinicians, 
researchers, public health officials and health policy experts 
to discuss  issues  that  face our women patients.   Elevating 
the  health  status  of  women  is  essential  to  improving  the 
health of the entire  community. We hope that you enjoy 




Sharon Marable, MD, MPH, is Medical Director, 
Office of Women’s Health Rhode Island Department of 
Health, and Clinical Assistant Professor, Community Health 
Brown Medical School. 
Maureen G. Phipps, MD, MPH, is  Director, Brown 
University/Women & Infants Hospital National Center 
of Excellence in Women’s Health, and Assistant Professor, 
Departments of Obstetrics and Gynecology and Community 
Health, Brown Medical School.













Reach Out and Read RI (RORRI) will host a benefit, 
Salon d’Art, at the Providence Art Club, 5:30 – 8:30 
p.m., Friday, November 4, to celebrate artists Mary 
Jane Begin and Christopher Denise. Their exhibit, 
“The Art of the Book,” will feature works from the 
artists’ recent works for children.
Reach Out and Read RI partners with pediatric primary 
care providers so that all children can grow up loving 
books. All proceeds from Salon d’Art will benefit 
RORRI. To learn more about Salon d’Art or Reach Out 
and Read, contact Sarah Gleason, Executive Director: 
(401) 521-1266, or reachoutandread-ri@cox.net. 
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Misconceptions  about  women 
and heart disease date back almost 250 
years  to William Heberden,  an  eigh-
teenth  century British physician who 
first described the symptom of angina 
pectoris  in  1768. He  noted,  “ Males 
are most liable to this disease, especial-
ly such as have past their fiftieth year. 




toms of acute myocardial infarction 




begun  to  appreciate  the  magnitude 
of  the  problem  of  cardiac  disease  in 










we  have  learned  more  about  gender 
differences  in  clinical  presentation 
which  influence  the  way  women  are 
approached  and  treated.  We  have 
known  since  the  early  publications 
of  the Framingham Heart Study  that 
women  tend  to  present  with  angina 
pectoris  and  men  with  either MI  or 





The  classic  symptoms of MI  are 











unusual  fatigue  (70.7%)  and  sleep 
disturbance  (47.8%).  The  most  fre-
quent acute symptoms were shortness 
of breath (57.9%), weakness (54.8%), 









The  greater  mortality  rate  of 
women with MIs has been attributed 
to the fact that they tend to be older 
than  men  at  the  time  of  presenta-










with  increasing  age  and was  not  sig-
nificant after age 74. The authors also 
found  more  co-morbid  conditions, 
higher  pulse  rates  and  lower  systolic 
blood pressures among younger wom-
en than among younger men but not 
in  older  women  compared  to  older 
men. Of  interest,  despite  these  find-
ings, younger women were  less  likely 
than  younger  men  to  present  with 
ST-segment elevation, and while they 





Women  undergoing  coronary 
artery bypass grafting (CaBG) have 
also been noted to have a higher mor-
tality  than  men.  This  has  tradition-
ally  been  ascribed  to  their  older  age. 
However,  just as  is the case with MI, 
an  analysis  of  51,187  patients  (30% 
women)  who  had  CABG  between 
1993  and  1999  found  that  younger 
women  had  higher  hospital  mortal-
ity  than men  (3.4%  versus  1.1%  for 





tality  (9.0%  in  women  versus  8.3% 
in men). Younger women undergoing 
CABG had more risk factors and co-
morbid  conditions  than  age-matched 
men  but  multivariate  analysis  found 
that  this  explained  less  than  30% 
of  the  mortality  difference  between 
younger men and women. 
This  mortality  difference  per-
sisted  after  adjustment  for  body  size 
and remains largely unexplained. Also, 
women in this study had angiographi-
cally  less  severe coronary artery dis-
ease (Cad) and better left ventricu-
lar (lV) function in all age categories.
In  contrast,  a  review  of  the  re-
sults  of  percutaneous coronary in-
tervention (pCi)  in  20016,8  found 
that  the  apparent  gender  difference 
in outcomes was negated after adjust-
ment  for  body  size. Using  data  from 
the National Cardiovascular Network 














with statins, even 
those at high 
risk, lowers their 
risk of cardiac 
events.”
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hospital mortality  rates  (1.8%  versus 












treatment  of  hyperlipidemia  take  no 




the  past  few  decades  several  large, 
randomized,  placebo-controlled  tri-




Of  the  three  large  primary  pre-
vention trials of statin use, two includ-
ed women:   the AFCAPS/TexCAPSg9 




WOSCOPS10,11  trial  enrolled  only 
men.)  The  AFCAPS/TexCAPS  trial 
was undertaken to determine if treat-
ment with lovastatin in subjects with-
out  clinically  evident  ASCVD  with 
average  total cholesterol (tC)  and 
ldl- cholesterol (ldl-C)  levels, 
but  below  average  hdl-cholesterol 
(hdl-C), would lead to a reduction 
in  the  risk  of  first  major  coronary 
event. This was defined as fatal or non-
fatal MI,  unstable  angina,  or  sudden 
cardiac death. AFCAPS/TexCAPS en-
rolled 997 women (15% of the study 
population). The  ages  of  participants 
ranged  from  45  to  73  years  for  the 
men and 55 to 73 years for the wom-
en. Overall,  the  trial  found a  statisti-
cally  significant  benefit  of  treatment 
with a 37% relative risk reduction  in 
the likelihood of first major coronary 
event.  However,  on  gender-specific 
analysis, while  13 primary  end point 
events occurred in women on placebo 
and  7  events  occurred  in women  on 
lovastatin,  this  was  not  a  statistically 
significant difference, given  the  small 
numbers of events.  (In contrast  there 
were  170  events  in  men  on  placebo 
compared  to  109  events  in  men  on 
lovastatin.)  
The  ASCOT-LLA was  a  trial  in 
hypertensive  patients without  known 
ASCVD but with at  least three other 




MI  or  fatal  coronary  heart  disease. 
Participants’  ages  ranged  from  40  to 
79 years. ASCOT-LLA enrolled 1,942 
women  (19%  of  the  study  popula-
tion).  Overall  the  trial  found  a  sta-













on  placebo  and  26  events  in  1,478 
women on statins, a difference that is 
not statistically significant (p = 0.56).
Despite  this  lack  of  evidence 
for  the  efficacy  of  statins  in  the  pri-
mary  prevention  of  coronary  events 
in  women,  both  the  Adult  Treat-
ment  Panel  III10,12  and  the  more  re-









even  those  at  high  risk,  lowers  their 
risk of cardiac events.
When  it  comes  to  secondary 
prevention  with  statins,  the  data  in 
women are  also not  as  compelling  as 
they are in men. During the past two 
decades  five  large  secondary  preven-
tion trials of statins in coronary heart 
disease  included  men  and  women. 
Women made up 25% of the 43, 957 
subjects enrolled in the 4S trial12,14, the 
Heart  Protection  Studym15,  the  Cho-
lesterol and Recurrent Events Trial14,16, 
the LIPID Trial15,17 and the PROSPER 
Trial16,18.  All  of  these  studies  showed 
a  statistically  significant  decrease  in 
the relative risk of coronary events in 
statin  treated  compared  to  placebo 
treated men.  In  contrast,  gender-spe-
cific analysis did not find a statistically 
significant  decrease  in  risk  of  cardiac 
events  in women in two of  these five 
trials  (LIPID  and  PROSPER),  while 
the other  three did demonstrate ben-
efit in women.





women  in  the  statin  trials. However, 
there is an alternative explanation. El-
evations  of LDL-C do not  appear  to 
be as potent a risk factor in women as 
they are in men. Even among kindred 
with Type  II  Familial  Hyperlipopro-
teinemia, the onset of coronary artery 
disease  in women lags 10 to 15 years 
behind  that  of  men  with  equivalent 
and  very  high  levels  of  LDL-C.17,19 
More  than  twenty  years  ago, women 
were  noted  to  have  significantly  less 
cholesterol  in  small  dense  LDL  and 
more  in  large  LDL  than  men.18,20 
Small dense LDL-C particles are more 
atherogenic  than  large  fluffy  LDL-C 
particles  and  since  women,  at  least 
before  the menopause,  have more  of 
the  latter,  it  is  likely  that  equivalent 
levels of LDL-C are less atherogenic in 
women than men.
In  support  of  this  hypothesis, 
a  follow-up  study  of  2,406 men  and 
2.056  women  enrolled  in  the  Lipid 
Research  Clinics  program  who  were 
free  of  vascular  disease  and  aged  40 




disease (CVd) mortality  in  women, 
whereas  TC,  LDL-C,  non  HDL-C 
and  low HDL-C  all  predicted  CVD 
mortality in men.19,21
More  recently,  it  has  been  sug-
gested  that  the  LDL-C  goal  for  very 
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The  recently  reported  results  of 
the  trial  of  aspirin  for  primary  pre-
vention  of  cardiovascular  disease  in 
women24,26    demonstrate  the  fallacy 
of  assuming  that  results  in  men  can 
be generalized to women. Among 39, 
875 healthy women 45 years of age or 
older who were  randomized  to  either 
100 mg of aspirin every other day or 
placebo  there  was  a  24%  reduction 
in  the  risk  of  ischemic  stroke  but no 
decrease in the risk of fatal or non-fa-
tal  MI  or  death  from  cardiovascular 










search…needs  always  to  account  for 
the evolutionary biology of sex.” 
The  Institute  of  Medicine  also 
noted  the  importance  of  taking  sex 
into  account:  “Sex matters.  Sex,  that 
is, being male or female, is an impor-
tant basic human variable that should 




In  summary  there  are  gender-
specific  differences  in  cardiovascular 
disease  including  age  at  presentation, 
risk factor weighting, response to medi-
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rolled  4162  patients  (22%  women) 
with  acute  coronary  syndromes  to 
receive  either  40  mg.  of  pravastatin 
or  80 mg.  of  atorvastatin. The  sub-
jects  in  the  atorvastatin  group,  who 
achieved a median LDL-C level of 62 
mg/dl,  had  a  statistically  significant 
16%  relative  risk  reduction  in  the 




therapy  with  high  dose  atorvastatin 
was  consistent  across  all  prespecified 
subgroups, including women.
The  preventive  guidelines  for 
women  also  recommend  treating 
non-HDL-C  and  low HDL-C  with 
a fibrate or niacin  if  they are abnor-
mal once the LDL-C goal is achieved. 
There  is  not  only  a  paucity  of  data 
to  support  this,  there  are  no  data. 
The  two  controlled  trials  of  fibrates 
(the  Helsinki  Heart  Study22.24  and 
VA-HIT23,25)  that  showed  benefit  in 
reducing cardiac events enrolled only 
men. 
Where do  these  studies  leave us 
with  respect  to  primary  prevention 
in women? Unfortunately, we do not 
have  evidence-based  answers  to  this 
question.  For  premenopausal  wom-
en  with  no  other  risk  factors  than 
an  LDL-cholesterol  above  the  cur-
rent  threshold,  statins have not been 
shown to decrease the risk of cardiac 
events.  There  is  clearly  no  harm  in 
counseling  ALL  patients  on  weight 
control,  regular  exercise  and  heart 
healthy diet. The use of statins in os-
tensibly healthy young women should 
probably  be  reserved  for  those  with 
Familial Hypercholesterolemia where 
LDL-C values are in the range of 300 
to  400 mg/dl.  In  addition,  their  use 
is  contraindicated  during  pregnancy 




WHEN  SUCH  PATIENTS  ARE 
HIGHLY  UNLIKELY  TO  CON-
CEIVE  AND  HAVE  BEEN  IN-
FORMED OF RISKS, we know little 
about  their  long-term  effects.  If  we 
are  proposing  to  treat  healthy,  low-
risk women for decades it behooves us 
to  be  certain  that  efficacy  is  beyond 
doubt and that benefits outweigh the 
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IRRITABLE BOWEL SYNDROME
Rossana Moura, MD
  irritable Bowel syndrome 
(iBs)  affects  up  to  20%  of  the  US 
population,with a 2:1  female-to-male 
ratio.1,2 IBS accounts for approximately 
3  million  physician  visits  annually,3 
12%  of  office  visits  to  primary  care 
physicians,  28%  of  all  referrals  to 
gastroenterologists;1  and  $1.7  billion 
to $10 billion in direct annual medical 
costs  (excluding medications) and  up 
to  $20  billion  in  indirect  costs  (e.g., 
lost  work  productivity  and  missed 
workdays).4,5
  The  higher  prevalence  of  the 
disorder  in  American  women  might 
reflect  their  increased  willingness  to 
seek  medical  advice.2  Other  factors 
influencing    consultation  in  IBS 
include  access  to  care,  symptom 
severity, fear of cancer, psychiatric co-




  Although  first  recognized  nearly 
2  centuries  ago,  IBS  remains  widely 
misunderstood  by  both  patients  and 
physicians.  Because  it  is  a  functional 
disorder,  no  organic  or  structural 
abnormality can be identified. The lack 
of objective findings can be frustrating 
and  the  differential  diagnosis  broad. 
For that reason, a number of symptom-
based criteria have been developed to 
try  to  simplify  and  standardize  the 
diagnostic approach to IBS; in 1978 the 
Manning criteria6  were published, and 
most  recently,  the  Rome  II  criteria. 
(Table) 17
CliniCal symptoms
  IBS  is  a  chronic  condition 
and  consists  of  abdominal  pain  or 
discomfort, associated with changes in 
bowel  pattern  (constipation,  diarrhea 
or alternation of both). Patients with 
IBS are usually categorized, according 
to  their  primary  bowel  habits,  as 
having  IBS-C  (less  than  three  bowel 
movements  per  week,  presence  of 
hard  stools,  straining  and  lumpy 
stools), IBS-D (more than three bowel 
movements per day, loose watery stools, 
and  urgency),  or  IBS-A  (alternating 
constipation  and  diarrhea).8  Women 
are more likely to report constipation-
predominant bowel habits, while men 
are more  likely  to  report  diarrhea.9,10 
Women are also more likely than men 
to complain of bloating. 
  Symptoms  usually  begin  in  late 
adolescence or early adult life, although 
the  problem  may  not  be  diagnosed 
for  years.  The  peak  prevalence  of 
IBS  occurs  in  the  third  and  fourth 
decades;  the  prevalence  decreases  in 






  Besides  the  symptoms  in  the 
Rome  II  criteria,  patients  with  IBS 
frequently  suffer  from  straining, 




complain  of  tiredness,  breathlessness, 
indigestion,  heartburn,  back  pain, 
headache, dizziness, urinary frequency, 
muscle  pains,  arthritis,  palpitations, 
anorexia,  sleeplessness,  menorrhagia, 
dyspareunia,  panic  attacks,  anxiety 
and depression.11 
  IBS  can  be  associated  with 
significant  emotional  distress,  poor 
quality of life, disability and increased 
health  care  costs.  Patients  with  IBS 
miss  three  times  as  many  work  days 
as  those  without  the  disorder;12  in 
“...in most cases 
of IBS, it is not 
what the patient 
eats that causes 
symptoms; rather, 
the simple 






ROME II Criteria for Irritable Bowel Syndrome
Pain or discomfort for 12 weeks, which need not be consecutive, in the preceding 12 months, 
associated with two of the following three features:
- Relief with defecation
- Change in stool frequency
- Change in stool appearance or form
Symptoms that cumulatively lend support to the diagnosis:
- Abnormal stool passage (straining, urgency or feeling of incomplete evacuation)
- Passage of mucus
- Bloating or feeling of abdominal distention
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fact,  after  the  common  cold,  IBS  is 
the  second  leading  cause  of  work 
absenteeism.13  It  is  not  uncommon 





state  that  their  symptoms  dominate 
their lives. 
pathophysiology
IBS  is  not  caused  by  a  single  factor; 
rather,  it  is  a  disorder  in  which  a 
number  of  physiologic  processes  are 
involved. These include abnormalities 
in  intestinal  motility,  alterations  in 
visceral  sensory  function,  changes 
in  central nervous system (Cns) 
processing of  sensory  information,  as 
well as psychosocial and other factors. 
altered gut motility
  Contractile  and  electrical 
activities  in  the  distal  colon  are 
exaggerated in patients with IBS, and 
can  be  demonstrated  by  increased 
rectosigmoid  contractile  activity 
in  response  to  a  meal,  injections 
of  cholecystokinin,  local  infusion 
of  bile  acids  and  distention  of  the 
rectum.14  Several  studies  have  shown 
an  abnormally  high  frequency  of 
discrete clusters of contractions in the 
jejunum  and  prolonged  propagated 
contractions in the ileum,15 but these 







  Patients  with  IBS  exhibit  more 
symptoms during transit of a standard 
meal16  and  during  transit  of  gases17 
than do normal subjects. There is also 
greater  sensitivity  to  rectal  distention 
at volumes lower than those that cause 










  There  is  well-documented 
relationship  between  an  attack 
of  gastroenteritis  and  subsequent 
development  of  chronic  symptoms 
compatible  with  the  diagnosis  of 
IBS. The  precise mechanism  for  this 
type  of  IBS  is  unknown;  but  several 
possibilities exist. An infectious process 
may  transiently  or  permanently 
injure  the  enteric  nervous  system;  or 
alternatively,  an  infectious  agent may 
initiate  a  cycle  of  chronic  mucosal 
inflammation  that  eventually  alters 
gut motility and/or sensation. Studies 
have  demonstrated  that  an  increased 
number of activated immune cells are 
present  within  the  intestinal  mucosa 
of patients with IBS.20 Post infectious 
IBS  patients  tend  to  be  women  and 








activities  of  the  intestines  occur 
through  coordinated  bidirectional 
communications  between  the  CNS, 
ans (autonomic nervous system), 
and ens (enteric nervous system), 
forming what  is known as  the brain-
gut  axis.22  GI  symptoms  can  result 
not  only  from  a  disorder  in  the  gut 
itself  but  also  from  dysregulated 
interactions  at  any  level  among  these 
control mechanisms of the gut.
  Using  positron  emission 
tomography  scanning  of  the  CNS 
during  rectal  balloon  distention, 
Silverman  et  al23  demonstrated  that 
IBS patients had increased activity  in 
the prefrontal cortex (an area associated 
with  anxiety  and  hypervigilance), 
and  reduced  activity  in  the  anterior 
cingulate cortex (an area important for 
opioid  binding),  when  compared  to 
healthy  subjects.    Another  study  that 
used  functional  magnetic  resonance 
imaging  also  reported  differences  in 











5-HT)  is  a  naturally  occurring 
neurotransmitter  and  signaling 
molecule.  Ninety-five  percent  of 
the  body’s  serotonin  is  found  in 






GI  tract,  serotonin  acts  via  intrinsic 
ENS  neurons  to  initiate  motor  and 
secretory  reflexes  and  via  extrinsic 
ENS neurons to initiate bowel-related 
sensations  such as pain and bloating. 
As  many  as  14  serotonin-receptor 








subtypes  are  considered  the  most 





increasing  during  the  late  luteal 
phase  and  early  menses.  The  effect 
of  menstruation  on  IBS  symptoms 
is thought to be mediated by ovarian 




progesterone  levels),  GI  symptoms 
(nausea,  constipation,  upper  GI 
distress) increase2 and that IBS patients 
on  oral  contraceptives  that  mimic 
naturally fluctuating ovarian hormones 
will continue to have amplification of 




of  IBS  is  threefold more  common  in 
women  with  dysmenorrhea  than  in 
those without.27 
food intoleranCe
  Although  studies  of  dietary 
restriction  followed by  the  sequential 
reintroduction  of  single  foods  have 
suggested  that  food  intolerance 
exists  in up  to  two  thirds of patients 
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with  IBS,28  true  food  allergies  are 
uncommon. Instead, in most cases of 
IBS, it is not what the patient eats that 
causes  symptoms;  rather,  the  simple 
act  of  eating  precipitates  bloating, 
gas,  and  abdominal  discomfort.  A 
number of  foods  are known  to cause 
symptoms that can mimic or aggravate 
IBS;  e.g.,    dairy  products,  legumes 
and  cruciferous  vegetables  (broccoli, 
cauliflower  and  cabbage),  carbonated 
beverages,  caffeine,  fatty  foods, 
alcohol, sorbitol and certain spices. 
psyChosoCial faCtors
  People  with  IBS  who  seek 
medical  help  are  more  likely  to 
suffer  from  coexisting  psychosocial 
stress  and  dysfunction  than  those 
who  do  not  seek  medical  advice.29,30 
Psychological disorders are  frequently 
seen  concomitantly  with  IBS,  but 
probably do not  cause the symptoms. 
Depression  and  anxiety  are  the most 
common  psychiatric  conditions, 
but  phobias,  obsessional  behavior, 
sleep  disturbance,  multiple  somatic 
symptoms,  hostile  feelings,  panic 
attacks,  and  alcohol  abuse  are  also 
more  common  than  in  healthy 
control  subjects.31 A history of major 
life  stress  (sexual,  physical  or  verbal 
abuse,  divorce  or  family  death)  plays 
an  important  role  in  modulating 
the  illness  experience  and  its  clinical 
outcome.  Patients  with  IBS  tend  to 
be  more  preoccupied  with  diseases 
and  tend  to  report  more  illness 
not  related  to  IBS.  Female  patients 
with  IBS  are  three  times  as  likely  to 
undergo  cholecystectomy,  twice  as 
likely  to  have  an  appendectomy  or 
hysterectomy, and 50% more likely to 





recommendations  developed  by  the 
ACG  functional Gastrointestinal 
disorders (fGid)  Task  Force 
advocate  a  stepwise,  symptom-based 
approach  to  the  diagnosis  of  IBS.33 
This  approach  involves  identifying 
the  patient’s  primary  symptoms, 
conducting a thorough patient history 
and  physical  examination  to  exclude 
signs suggestive of other diagnosis and 




or  nocturnal  diarrhea,  unintentional 
weight  loss,  gastrointestinal  bleeding, 
anemia  or  family  history  of  colon 
cancer,  directed  diagnostic  testing 
should  be  performed  to  rule  out  the 
possibility of organic disease.
  Several  intestinal  disorders  have 
similar  symptoms,  such  as  lactose 
intolerance, celiac sprue, inflammatory 
bowel disease and microscopic colitis. 
The  danger  of  missing  a  diagnosis 
needs to be balanced against the cost of 
performing unnecessary investigations 
and  the  risk  of  reinforcing  illness 
behavior.  Many  physicians  are 
concerned  about  diagnosing  IBS 
confidently  without  performing  any 
objective  tests.  A  complete  blood 




If  diarrhea  is  the  patient’s  primary 
complaint,  stool  samples  should  be 
tested. Serologic tests for celiac disease 
can  also  be  performed  in  patients 
with  persistent  diarrhea.  Flexible 
sigmoidoscopy may be recommended 
for  younger  patients  with  rectal 
discomfort or bleeding. A colonoscopy 
is  warranted  in  patients  who  are  50 
years  of  age  or  older,  have  a  strong 
family history of inflammatory bowel 
disease  or  colorectal  cancer,  or  show 
evidence  of  anemia.  In  patients  with 
diarrhea,  random  colon  biopsies  can 





several ways  to manage  this  disorder, 
according  to  the  type  and  severity of 
symptoms. The chronic nature of IBS 
and  the  challenge  of  controlling  its 
symptoms can be frustrating for both 
patients  and  doctors.  An  effective 
physician-patient relationship plays an 
important part of  treatment. Patients 
need  to  be  educated  and  reassured 
about their condition.
   The  efficacy  of  drugs  in  IBS  is 
difficult  to  demonstrate  due  to  the 
high placebo response rate. The same 
applies  to  dietary  restrictions  and 
alternative  medicine.  Nonetheless, 
such therapies should not be dismissed 
simply  because  they  have  not  been 
verified  in  randomized  controlled 
trials.  A  symptom  diary  may  help 
pinpoint  possible  triggers  and  guide 
treatment  options.  Any  food  that 
appears to precipitate symptoms should 
obviously  be  avoided.  Increasing 
dietary  fiber  (either  by  adding  foods 
to the diet or using fiber supplements) 
can relieve constipation, but may also 
help  in diarrhea  since  it  can  improve 
the consistency of stools. Dietary fiber 
supplements  should  be  increased  to 
the prescribed dose over several weeks 
to  reduce  symptoms  of  excessive 
intestinal  gas.  Gas-producing  foods, 
gum  and  carbonated  drinks  should 
be avoided if the patients suffer from 
bloating.  Lactose  intolerance  is  very 
common  in  the  general  population, 
and avoidance of dairy products may 
be  helpful  in  reducing  symptoms  of 
IBS.
  In  patients  with  abdominal 
pain,  anticholinergic  drugs,  which 
have  antispasmodic  effects,  may 
be  prescribed  to  relieve  severe 
cramping.  Drugs  in  this  category 
include  dicyclomine  (BentylR)  and 
hyoscyamine (LevsinR). Common side-
effects include dry mouth and eyes and 
blurred  vision.  Antidepressants  may 
also be helpful due to a pain relieving 
effect  that  is  independent  of  their 
depression relieving effect.34 Tricyclics 
slow  movement  of  contents  through 





hydroxide,  lactulose  or  polyethylene 
glycol solutions can also be prescribed 
for  constipation.    For  diarrhea-
predominant IBS, antidiarrheal drugs 
such  as  loperamide  or  diphenoxylate 
with  atropine  can  help  slow  bowel 
transit time. These drugs should only 
be  used  as  needed,  and  rarely  on  a 
continuous  basis.  Cholestyramine,  a 




were  developed  for  the  treatment 
of  IBS.  Women  treated  with  the  5-
345
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3
  receptor  antagonist  alosetron 
(lotronexR)  experience  significant 
improvements  in  abdominal  pain 




was withdrawn  from  the market  that 
same  year due  to  reports  of  ischemic 
colitis.  In  response  to  patient  and 
public  demand,  the  FDA  reinstated 






  receptor  antagonist,  in  women 
and  men  with  diarrhea-predominant 
IBS.36 After the review process, the FDA 
recently  notified  the  manufacturing 
company  (Solvay  Pharmaceuticals) 





  agonist. This  drug  accelerates 
bowel  transit37,  relieving  global  IBS 
symptoms,  pain  and  constipation. 
Although  initially  indicated  only  for 
female  IBS-C  patients,  it  was  also 
recently shown to be effective for the 
treatment  of  chronic  constipation  in 
men and women and is also approved 
for  this  indication.38  Headache  and 
diarrhea  are  the  most  commonly 
reported  adverse  events.  A  recent 
update on the safety of tegaserod was 
issued by the manufacturer about rare 




meditation  and  hypnotherapy,  can 
be  considered  in  IBS  patients  with 
moderate  to  severe  symptoms,  when 
patients have failed medical treatments, 
or when there  is evidence of stress or 
psychological  factors  contributing  to 
symptom exacerbations.39 
ConClusion
  In  the United States, up  to 70% 





With  a  careful  history  and  physical 
examination,  it  is  often  possible  for 
the  physician  to  make  a  positive 
diagnosis of IBS. It is important in the 
initial  visit  that  psychosocial  factors 
that may contribute  to  symptoms are 
elicited  from  the  patient.  It  is  also 




substantial  physical  discomfort  and 
emotional  distress,  the  vast  majority 
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Update in Surgical Management of Female 
Stress Urinary Incontinence
 It  is  estimated  that  the  rate  of 
stress urinary incontinence (sUi) is 




der will  increase.    It  is predicted  that 
by year 2030, the number of women 
over age 55 will almost double to over 
60  million.3    The  predicted  shift  in 
demographic  makeup  of  the  United 
States and improved overall health will 
lead  to  an  increase  in  the number of 
women receiving care for SUI.4  
  Although  rarely  life  threatening, 
SUI  may  precipitate  insecurity,  em-
barrassment, depression,  social disen-
gagement,  and/or    psychological  and 
functional  decline.    Spousal  relation-
ships  can  be  negatively  affected  and 










  In  the past urinary  incontinence 
was  considered  to  be  a  natural,  and 
unavoidable, result of aging.  Despite 
treatments,  it  is  estimated  that  only 
13% of women will seek help for this 
condition.7  Some women, with mild 
symptoms do not  feel  that  treatment 
is needed.   Other women are embar-
rassed  to  speak  with  a  health  care 
provider  about  the  condition;  some 







incontinence  with  patients  and most 
physicians  felt  inadequately  prepared 
to  discuss  options.8    As  minimally 
invasive  surgical  treatments  evolve, 



















have  a  satisfactory  response may  not 
need further testing.
  Women who  do  not  respond  to 
conservative therapy will need a more 
detailed evaluation.  A detailed history 
includes  questions  about  frequency 
and  amount  of  leakage,  precipitating 
factors,  impact  of  leakage  on  daily 
life and pad use pelvic organ prolapse 
symptoms, urinary urgency, nocturia, 
incomplete  bladder  emptying,  hema-









  Further  assessment  of  bladder 
function  with  urodynamic  testing  is 
recommended  for  women  with  an 
unclear diagnosis, women considering 
surgical treatment, women with an el-
evated  postvoid  residual  volume  or  a 
neurologic  condition,  significant  pel-
vic  organ  prolapse,  or  prior  attempts 
at  surgical  correction.    Urodynamic 
testing provides a more precise evalu-
ation  and  includes  a  combination  of 
tests  measuring  urethral  and  bladder 
function  during  bladder  filling,  stor-
age, and emptying.  
treatment
  The  treatment  goal  for  SUI  is 









report  satisfaction  even  if  they  are 
not  completely dry.9, 10   Conservative 
options  should  always  be  discussed. 
These  include  behavioral  modifica-
tion (fluid intake modification, weight 
loss  for  obese  patients),  pelvic  floor 
exercises with or without biofeedback, 
and vaginal supportive devices.  Phar-
macologic  therapy  includes  tricyclic 
antidepressants  (imipramine)  which 
facilitate bladder storage and  increase 
urethral  resistance.   Duloxetine, a  se-
rotonin and norepinephrine  reuptake 
inhibitor,  is being  investigated  in  the 
treatment of SUI.11
  Patients who are dissatisfied with 
conservative  measures  may  opt  for 
surgical  treatment.    The  choice  of 
procedure is guided in part by severity 
of  SUI,  presence  of  associated  pelvic 
prolapse, voiding function, patient co-
morbidities and patient preference. 






“It is estimated 




35% in older 
women and 28% in 
younger women.”
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compression  against  a  stable  subure-
thral  support.    Trans-abdominal  ret-
ropubic  suspensions  involve  entering 
the  retropubic  space,  placing  sutures 
in  the periurethral  fascia and suspen-
sion  to  nearby  structures  including 
the  periosteum of  the  pubic  bone  or 
Cooper’s ligament.12-15
  In  1997,  members  of  a  clinical 
guidelines  panel  from  the  American 
Urological  Association  reviewed  the 
literature  and  outcomes  data  on  sur-
gical treatment of female SUI.16   The 
panel  concluded  that  retropubic  col-
posuspensions  were  effective  in  the 
treatment  of  SUI,  with  median  cure 
rates of 84% (95% CI 79-88%) at 2 
years  or  greater.    Postoperative  com-
plications  of  retropubic  procedures 




  A  laparoscopic  approach  may 
also  be  used  to  perform  the  Burch 
colposuspension.    Advantages  of  the 
laparoscopic approach include smaller 
skin  incisions,  quicker  post-operative 
recovery and return  to work.   Disad-
vantages may include longer operative 
times,  especially  during  the  surgeon 
training  period,  and  technical  diffi-
culty.  
  There  is  little  level  1  evidence 
comparing  the  laparoscopic approach 
with  the  traditional  abdominal  ap-
proach.    In  2004,  the  Cochrane  In-
continence  Group  reviewed  8  ran-
domized trials and concluded that the 
cure  rate  for  laparoscopic  colposus-
pension  trended  lower  compared  to 
the open approach (relative risk 0.91; 
95% CI 0.82-1.01).20   However, dif-
ferent  techniques  and  modifications 
to  overcome  laparoscopic  suturing, 
and  inconsistent  numbers  of  sutures 
were  used  between  studies,  making 
comparisons  difficult  and  unreliable. 
The long-term success of laparoscopic 
colposuspension  remains  unclear  and 


























or  leg  incision  to  harvest  the  fascia. 
There  are  also  a  variety  of  synthetic 
materials including Gore-Tex, prolene, 
and Mersilene.    Comparative  studies 
of ideal sling materials are lacking.
Similar  to  retropubic  colposus-
pensions,  bladder  neck  slings  have  a 
risk of voiding dysfunction of 12.8%, 
prolonged  urinary  retention  of  8%, 
and  de novo  urge  symptoms  of  7%. 
The Urinary  Incontinence Treatment 
Network,  a  National  Institutes  of 
Health-sponsored  network  including 
9 centers, is comparing long-term (24 




tension free Vaginal tape 
sling (tVt):
  The  search  for  more  minimally 
invasive  sling  procedures  led  to  the 
evolution  of  the  TVT™  (Gynecare, 
Sommerville,  NJ)  sling.    The  TVT 
aims  to  restore  continence  through 
compensation  of  the  pubourethral 
ligaments  and  formation  of  a  firm 
backboard  for  the  urethral  to  close 





  The TVT was  introduced  in  the 
1990s;  initial  success  rates  were  re-
ported  through  case  series  from  in-
dividual  institutions.  Ulmsten,  et  al 
reported  that  at  2-3  years  following 
the TVT, 86% of women were dry, an 




10.6%  improvement  rate,  and  a  low 
4.5% failure rate.23
  The  TVT  may  be  performed 
under  local  or  minimal  regional  an-




severe  than  traditional  slings  and  ret-
ropubic colposuspensions.  Two small 




is  then  passed  vaginally  through  the 
suprapubic incision on either side with 
4-mm  needles  and  the  mesh  is  situ-
ated  at  the  midurethra,  tension  free. 
There is no need to suture the mesh in 
place.  Variations of the TVT include 
the  SPARC  ™  (American  Medical 
Systems, Minnetonka, Minn), a “top-
down” method of passing the needles. 
  Complication  rates  are  overall 




erosion  is  low,  <1%.24,  25     The most 
common  intraoperative  complication 
is  bladder  perforation  (3.6%),  but 
long-term sequela following this event 
are  rare.   Although rare,  there are  re-








the  two  procedures.    Depending  on 
how missing  data was  treated,  objec-
tive cure ranged from 63-85% for the 
TVT group and 51-87% for  the col-
posuspension  group.   Women  in  the 
TVT  group  were  less  likely  to  have 





  Given  the  rare  but  potentially 
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was first described in 1998; based on 
early case series, the clinical effective-
ness  was  similar  to  the  TVT.    The 
TOT is also a midurethral sling, thus 








the  obturator  membrane  and  passes 
through each corresponding groin in-
cision.   
  Like  the  TVT,  the  TOT  is  of-
ten  performed  under  local  or  light 
regional  anesthesia  on  an  outpatient 
basis.    Operative  time  is  short,  and 
patients  recover quickly.   A proposed 
advantage  of  the TOT  is  a  decreased 
risk of bleeding, as there are no needles 
passed  through  the  retropubic  space 
and  the  great  vessels  are  not  at  risk. 
This  also  theoretically  decreases  or 
eliminates the risk of bowel and blad-




and  voiding  dysfunction,  due  to  less 
risk of over-correction.  
  The  greatest  risk  with  this  ap-
proach may be injury to the obturator 
nerve  and  vessels.    In  cadaver  stud-
ies, the obturator nerve branches and 
bundle  are  on  average  2.5-cm  from 
the mesh.28  The most medial obtura-





query  of  the MAUDE  database,  (an 




is  0.0001%.29    However,  this  physi-
cian-initiated  database  likely  under-
estimates  the  true  complication  rate. 














space  should  be  avoided  (ie:  women 
with prior  retropubic  surgery, history 
of retropubic bleed, history of recon-
structive  abdominoplasty).    Well-de-






tion during  the  storage  phase  and  to 
maintain  coaptation  during  episodes 
of increased intra-abdominal pressure. 
Bulking  agents  may  be  administered 
under local anesthesia as an outpatient 
procedure or performed in the office. 
The  agents  may  be  injected  at  the 
bladder neck using a periurethral or a 
transurethral approach.  
  Agents  include  glutaraldehyde 
cross-linked  collagen,  a  highly  puri-
fied  suspension  of  bovine  collagen 








  Carbon  beads  are  composed  of 
non-absorbable  pyrolytic  carbon-








  The  food and drug admin-
istration (fda)  recently  approved 
ethylene  vinyl  alcohol  (Tegress  ™, 
CR Bard)  for  transurethral  injection. 
At  body  temperature,  the  polymer 
precipitates  into  a  spongiform,  non-


















minimally  invasive  procedures  may 
improve  a  woman’s  symptoms  and 
quality of life.  As the population ages, 




Diagnosis and Evaluation of Urinary Incontinence
History
• Identify symptoms and severity
• Impact on quality of life, degree of bother
• Rule out chronic illnesses that may affect fluid balance
• Review medications with possible adverse urinary effects (eg, anticho-
linergics, diuretics, antidepressants, antipsychotics, alpha-blockers)
• Review prior pelvic surgeries
Physical Examination
• Assess neurologic function
• Assess pelvic organ support
• Cough stress test or objective demonstration of stress incontinence
• Post void residual to rule out retention
• Urinalysis and culture to rule out infection
Urodynamic studies*
• Confirm stress incontinence
• Assess for urge urinary incontinence
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Table 2
Treatment Options for Stress Urinary Incontinence
Absorbent products





 Serotonin-norepinephrine reuptake inhibitors
Surgical treatment
 Retropubic colposuspension
 Bladder neck sling
 Mid-urethral sling
 Urethral bulking agents
____________________________________________
   Vivian W. Sung, MD, is a Fellow, 
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in Clinical Trials and Epidemiology,
Department of Obstetrics and Gynecol‑
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 Obesity  rates  are  reaching 
epidemic  proportions  in  the  United 
States and other industrialized nations. 




affects  34.0%  of  women  and  28.1% 
of men.  Non-Hispanic black women 
have the highest rates of obesity: nearly 
half  are  obese.  (Table  1)    Obesity 
is  six  times  more  prevalent  among 
women of low as compared with high 
socioeconomic status.
Obesity  causes,  exacerbates,  and 
predisposes to many diseases affecting 
women, including heart disease, breast 
and  endometrial  cancers,  diabetes, 
urinary  incontinence,  and  arthritis.1 




increase  the  risk  for  the development 
of diabetes.2, 3  
Fortunately,  modest  weight 
losses  of  5%-10%  of  body  weight 





cholesterol,  blood  glucose  levels, 
sleep  apnea,  osteoarthritis,  and  gout 
are  observed.    In  a  recent  large-scale 
study,  increased  physical  activity  and 
loss of 7 kg prevented or delayed the 
onset of type 2 diabetes in individuals 
with  impaired  glucose  tolerance. 
Participants  who  were  assigned  to 
lifestyle intervention reduced their risk 
of developing type 2 diabetes by 58%. 
Participants  receiving  standard  care 
plus  pharmacotherapy  (metformin) 
reduced their risk of type 2 diabetes by 
31%:  lifestyle  intervention was  twice 
as effective as medication.  
key Components of 
suCCessful Weight 
Control
Much  of  what  we  know  about 
lifestyle change to promote successful 
weight loss is derived from the national 
Weight Control registry (nWCr) 
data.    The  NWCR  is  a  registry  of 
individuals  who  have  successfully 
maintained  a  loss  of  at  least  13.6  kg 
for  at  least  1  year.4    However,  the 
5,000 participants in the NWCR have 
far  exceeded  these minimum criteria; 
on  average,  they  have  lost  almost  70 
lb and kept it off for 6 years.  Research 
from  the  NWCR  and  randomized 
controlled trials have identified several 
key  lifestyle  changes  for  long-term 
successful  weight  control.    (Table  2) 
These  include  consumption  of  a  low 
calorie, low fat diet, engaging in high 
levels  of  physical  activity,  and  self-
monitoring.  
Consumption of a low calorie, low 
fat diet.  Although the optimal degree 




fat  intake  <30%  of  calories.    Data 
from  the  NWCR  support  these  low 
calorie, low fat recommendations.  In 
addition,  78%  of  registry  members 
reported eating breakfast every day of 
the  week.    Maintaining  consistency 
in  the  diet  also  appears  to  be  a  key 
characteristic of NWCR participants; 
most  participants  reported  that  their 
eating was the same on weekends and 
weekdays  and  on  holidays/vacations 
and the rest of the year. 
Recently, there has been renewed 
interest  in  diets  that  severely  restrict 
carbohydrate  intake,  like  the  Atkins’ 
and  South  Beach  diets.    Such  diets 
are  only  beginning  to  be  formally 
evaluated  in  weight  loss  trials. 
Short-term  evaluations  have  found 
significantly  greater  weight  losses 
with  low  carbohydrate  regimens 
relative  to  low  fat,  low  calorie 
regimens.  Two long-term evaluations 
of  low  carbohydrate  diets  found  no 
significant differences relative  to  low-
fat diet controls at 1 year.5, 6  Although 
low-carbohydrate  dieters  are  often 
allowed to eat as much protein and fat 





Self‑monitoring of body weight, 
food intake, and physical activity.   Self-
Suzanne Phelan, PhD, and Rena R. Wing, PhD
Obesity in Women
“… modest weight 
losses of 5% -10% 
of body weight 
are sufficient 
to control, 




Table 1.  Proportion of Women Overweight or Obese 
(Females aged 20 to 74 years by race and Hispanic origin, 1999–2002)
Race/Ethnicity
Overweight 
(BMI greater than 
or equal to 25)
Obese 








Mexican American 71.4% 38.9%
Age adjusted to the U.S. year 2002 standard population. 
Source: Centers for Disease Control and Prevention, National Center for Health 
Statistics, National Health and Nutrition Examination Survey, Health, United 
States, 2002.
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monitoring  appears  to  be  another 
important  ongoing  strategy  for 
successful  weight  loss.    Seventy-five 
percent  of  members  in  the  NWCR 
weighed  themselves  at  least  once  per 
week,  and  44%  weighed  themselves 
daily.    Additionally,  50%  of  registry 




in  successful  weight  management. 
Notably,  self-monitoring  is  often not 
totally  accurate;  in  fact,  estimates  of 
dietary  intake  obtained  from  such 
recording underestimate actual intake 
by  30%  on  average.   Therefore,  this 
technique  should  be  viewed  more 
as  a  behavior  change  tool  than  as  an 
assessment technique.
Engaging in High Levels of Physical 
Activity.  Correlational studies, as well 
as  controlled  trials,  show consistently 
that  persons  who  engage  in  regular 
physical  activity  are  the  ones  most 
likely  to  maintain  a  reduced  weight. 
Almost  all  participants  (91%)  in  the 
NWCR  reported  engaging  in  regular 
physical  activity. On average, women 




This  amount  of  physical  activity  is 
comparable  to  walking  about  28 
miles/week or about an hour per day 
of moderate intensity physical activity. 
This  amount  of  physical  activity  is 
also consistent with the United states 
department of  agriculture’s (Usda) 




to  sustain  weight  loss  in  adulthood. 
Most  NWCR  subjects  meet  this 
recommendation.  
Results  of  other  studies  support 
the recommendation for high levels of 
physical activity and suggest that high 
levels  may  be  necessary  to  prevent 
weight regain after weight loss.  Jakicic 
et  al.8  reported  that  greater  levels  of 
physical  activity had minimal  impact 
on  6-mo  weight  loss  in  women 
who  were  reducing  energy  intake. 
However,  the  higher  amounts  of 
exercise appeared to be more effective 
for  prevention  of  weight  regain.  It 
was  reported  that  women  engaging 
in ~280 min/wk of at  least moderate 
intensity  physical  activity  (i.e.,  brisk 
walking) throughout the 18-mo study 
reduced their body weight by 13 ± 8.0 
kg,  whereas  exercising  <200  min/wk 
or  <150  min/wk  resulted  in  weight 
loss  of  8.5  ±  5.8  and  3.5  ±  6.5  kg, 
respectively. 
Dividing  physical  activity  into 
multiple  10-min  bouts may  facilitate 
initial adoption of activity in previously 
sedentary  women.    Home-based 
exercise programs and the use of home 
exercise equipment may also enhance 
exercise  adherence  and  improve  the 
maintenance of weight loss.  
treatments speCifiC for 
Women  
Several  treatments  have  been 
tailored  to  address  weight  concerns 
of  women.    Although  the  basic 
elements  of  treatment  are  consistent 
with standard weight control practices 
(i.e., modifying diet, physical activity, 
and  self-monitoring),  the  timing  and 
structure of treatment may be tailored 
to address the needs of women. 
Pregnancy  One  period  when 
obesity  prevention  efforts  may  be 
particularly  effective  for  women  is 
the  period  surrounding  pregnancy. 
Although  studies  of  the  general 
population  have  reported  average 
weight gains of only 0.4 to 3.8 kg more 






Table 2. Key Strategies for Long Term Successful Weight Loss
Consume a low calorie diet 1200-1500 kcal/day for women1500-1800 kcal/day for men
Consume a low fat diet <30% kcal/day from fat
Consume breakfast Eat breakfast daily
Increase physical activity Goal of 60 minutes/day
Self-monitor weight, intake, and 
exercise Record daily
   “Learn from fellow physicians in Rhode Island how to successfully redesign your
    approach to diabetes in a way that promotes patient and doctor satisfaction while
    earning financial incentives for your practice”…
    Chris Campanile MD, PhD     Chairperson, RI Chronic Care Collaborative
Attend the
      Rhode Island Chronic Care Collaborative
2nd Annual Outcomes Congress
Jointly Sponsored by Brown Medical School
          November 2, 2005
             Crowne Plaza Hotel
801 Greenwich Ave
          Warwick, RI 02886
“The collaborative turns evidence
based medicine into office
practice by providing a structure
for physician, staff and patient
ideas to modify and improve our
delivery of care.”
Mark Schwager, MD
University Medical Group-East Greenwich
Space is limited - Register by October 26, 2005
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We’ll be there for you tomorrow.
By careful underwriting, aggressive claims defense and comprehensive risk management services,
ProMutual Group offers doctors a clear advantage in liability protection. As a result, our doctors enjoy
peace of mind knowing that their reputations and personal assets are secure.
However, in today’s environment even the best doctor can have a frivolous lawsuit brought against them.
When you consider that defending a malpractice lawsuit is an expensive proposition there is a school of
thought that suggests we could save money by settling more cases… but we disagree. We’re in the
business of protecting doctors and over the last several years, integrity has been our best accounting
formula. ProMutual Group has proven that decisions based on protecting good doctors have, in the end,
kept our company financially secure and allowed us to offer doctors steadfast protection.
One way we accomplish our goal is by helping doctors avoid risk. That is why we maintain the largest
risk management staff in our area and why we pioneered such techniques as peer-rated office appraisals.
We’ll be there for you today, tomorrow, and for your entire career. Call one of our agents today.
Financial Integrity, Physician Loyalty
101 Arch Street, Boston, Massachusetts 02110 ■ 888-776-6888 ■ WWW.PROMUTUALGROUP.COM
Dr. Ballarin-Feldman, insured since 1984
Bill Mende
Mastors & Servant
East Greenwich ■ 401-885-5700
Joanne Peacock
AON Risk Services of RI
Providence ■ 401-331-7700
William Allen
Troy, Pires & Allen
East Providence ■ 401-431-9200
Nat Calamis
Starkweather & Shepley













Contact one of our Rhode Island agents:
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The  single  strongest  predictor 
of  weight  gain  from  pre-to  1-year 
post-pregnancy  is  the  magnitude  of 
weight gained during pregnancy. The 
National Academy of Science institute 
of Medicine (ioM)  has  formulated 
recommendations  for  healthy  weight 
gain  during  pregnancy.   However,  in 
a  recent  study  of  500  pregnancies  in 
Rhode  Island,  we  found  that  more 
than  one-third  of  normal  weight 
women and two thirds of overweight 
women exceeded these recommended 
levels;  similar  findings  have  been 
observed elsewhere.9, 10  
Women  with  excessive  weight 
gains  during  pregnancy  are  at 
increased  risk  of  retaining  significant 
degrees  of  weight  postpartum.11 
Moreover,  weight  gains  that  exceed 
the  recommended  levels  have  been 
connected  to  hypertension,  diabetes, 
pre-eclampsia,  cesarean  sections,  and 
babies that are large for gestational age. 
Helping women gain the recommended 
amount  during  pregnancy  through 
healthy  eating,  physical  activity, 
and  self-monitoring,  could  prevent 
excessive  weight  retention  and  its 
associated  complications.    The  years 
preceding and/or following pregnancy 
may  provide  other  opportunities 
(“teachable moments”) for practitioners 
to help women achieve and maintain 
a  healthy  body weight.  Breastfeeding 
for one-year post-partum may slightly 
reduce one-year weight retention, but 
has  other  benefits  for  maternal  and 
infant  health.     Our  clinic  is  seeking 
to determine whether the incidence of 
pregnancy-associated weight retention 
and  obesity  can  be  reduced  through 
behavioral  lifestyle  interventions  that 
target  the  pre-pregnancy,  pregnancy, 
and/or the postpartum periods. 
Menopause    Another  high-risk 
time  for  weight  gain  in  women  is  the 
period  surrounding  menopause.  In  a 
longitudinal  study  of  541  healthy  pre-
menopausal  women,  aged  42  –  50  at 
study entry, the average weight gain was 
5  pounds  over  3  years  and  12  pounds 
over  8  years.  This  gain  was  associated 
primarily with aging, rather than with the 
hormonal changes of menopause per se. 
Moreover,  decreased  physical  activity 
was  the  most  consistent  behavioral 
factor associated with this gain.
The  menopausal  transition 
is  associated  with  a  worsening  in 
cholesterol  levels,  an  effect  which  is 
particularly  pronounced  in  women 
who  gain  weight  at  this  time. 
Therefore,  lifestyle  intervention 
aimed  at  modifying  dietary  and 
physical activity behaviors might help 
prevent  both  the  weight  gain  and 
the  worsening  in  cardiovascular  risk 
factors. The Women’s Healthy Lifestyle 
Project  12  was  a  5-year  randomized 
clinical  trial  testing  the  hypothesis 
that  lifestyle  intervention  could 
reduce  the magnitude of weight gain 











to  lose  weight  initially  to  offset  the 
anticipated  weight  gain.    Women 
who were normal weight  (BMI < 24 
mg/dl) were encouraged to lose 5 lbs; 
those  with  a  BMI  of  25  –  26  were 
encouraged to lose 10 lbs; those with 
a  BMI  of  27  –  34  were  encouraged 
to  lose  15  lbs.  Women  consumed  a 
low calorie/low fat diet and increased 
physical  activity  to  a  goal  of  1000  – 
1500 kcal/week. Intervention activities 
included 6 months of group meetings 




The  intervention  was  effective 
in  blunting  the  anticipated  gain;  the 
intervention group lost 10.8 lb during 




This  contrasted with  a  5.2  lb weight 
gain in the control group.  At the end 
of the study, 55% of the intervention 






The  intervention  also  produced 
significant  effects  on    lipids,  blood 
pressure,  insulin,  and  glucose.  At 
month  54,  LDL  cholesterol  in  the 
intervention  group  had  increased  by 
3.5 mg/dl, whereas the control group 
had  increased by 8.9 mg/dl  (p  .009). 
Waist circumference decreased 2.9 cm 
in  the  intervention  group  compared 
with  .5  cm  in  the  control.  Thus, 
intervention  at  this  time  period may 
have multiple benefits for women.
Urinary incontinence      Urinary 
incontinence  may  be  alleviated  by 
weight loss. An estimated 13+ million 
women  in  the  US  have  urinary 
incontinence; including approximately 
25% of reproductive age women and 
50%  of  postmenopausal  women. 
Epidemiological  studies  show  that 
obesity  is  a  strong  risk  factor  for 
incontinence;  each  5-unit  increase 
in BMI leads to 60% increase  in risk 






randomized  trial  with  42  overweight 
or  obese  incontinent  women:  22 
were  randomized  to  an  immediate 
weight loss condition, 20 to a delayed 
treatment  control.  The  weight  loss 
intervention  included  a  very  low 





incontinence  episodes  compared  to  a 
15%  reduction  in  the  control  group. 
In  the  intervention  group,  16%  of 






The  nih (niddK)  recently 
funded  a  multi-center  clinical  trial, 
pride (program to reduce 
incontinence through diet and 
exercise),  testing  the  effectiveness  of 
weight  loss  for  women  with  urinary 
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Table 3.
NIH-funded Studies Currently Recruiting at the 
Weight Control and Diabetes Research Center (401-793-8940)
PRIDE: Program to Reduce Urinary Incontinence by Diet and Exercise.  
This study provides an 18-month weight loss program for overweight 
women aged >30 years with > 10 incontinent episodes/week. 
LEAP: Lifestyle, Eating and Activity Program.  This 18-month program is 
recruiting pairs of overweight individuals who live together (e.g., spouses) 
to examine the effects of modifying the home environment.
LITE:  Living Lean in a Toxic Environment.  Individuals who are normal 
weight or have successfully reduced from obese to normal weight are 
provided information about their current eating and exercise habits. 
incontinence.  Researchers  at  the 
Weight Control & Diabetes Research 
Center,  The  Miriam  Hospital,  are 
one  of  the  Centers  participating  in 
this  trial. A  total  of 165 women will 
be  studied  at  The  Miriam  Hospital. 
(Table 3)  
ConCerns aBout Weight 
loss in Women
In the past, dieting was criticized 
for  limited  effectiveness,  causing 
adverse  emotional  responses  or 
precipitating binge  eating.   However, 
recent  studies  and  a  review  by  the 
National Task Force on the Prevention 
and Treatment have put these concerns 
to  rest.    The  review  concluded  that 





and  physical  benefits.    In  particular, 




may  result  in  a  loss  of  bone mass  in 
overweight women.  In a randomized 
study,  women  in  the  weight  loss 
intervention who  lost 3.2 kg over 18 
months  experienced a 2-fold  increase 
in  rate  of  hip bone mineral density 
(BMd)  loss compared to the control 
group,  which  gained  1.5  kg.14    A 
similar  pattern  was  seen  for  BMD 
change  at  the  spine,  although  the 
difference was non-significant.   Large 
increases  in  physical  activity  helped 
reduce the amount of spine BMD loss, 
but  not  hip  loss.    Since  osteoporosis 
is  an  important  health  concern  for 
women,  further research  is needed to 
determine whether the effect of weight 
loss  on  BMD  can  be  attenuated  by 
aerobic or resistance training. 
ConClusion
Obesity  affects  the  health  of 
millions  of  women  nationwide. 
Successful weight loss typically involves 
a  combination  of  consuming  a  low 
calorie, low fat diet, engaging in high 
levels of physical activity, and frequent 
self-monitoring.    Promoting  such 
lifestyle  changes  during  critical  life 
junctures  for women,  such  as  during 
pregnancy  and  menopause,  may  be 
effective  in  treating  and  preventing 
obesity-related diseases in women. 
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A 28-year-old woman presented with one month of 
abdominal pain.   The CT scan and ultrasound  images 
displayed  are  consistent  with  a  large  simple-appearing 
cystic structure in the abdomen and pelvis measuring 20 
x 17 x 8 cm, arising from the right ovary.  The CT scan 
revealed no  free fluid,  lymphadenopathy, or  suspicious 
lesions in the abdomen and pelvis.  The ultrasound char-
acteristics  were  highly  suggestive  of  a  benign  process. 
The mass  had  no malignant  features,  such  as  internal 
septations,  solid  components,  papillary  projections,  or 
internal  echoes.   The  literature  suggests  that  the  sensi-














ogy was  consistent with  a  benign  serous  cystadenoma. 
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A 20 cm Mass in a 28 Year-old Woman
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ed  on  screening  mammography  and 
biopsied  under  ultrasound  guidance 
with good correlation of size.  She has 
a clinically negative axilla and no sig-
nificant  medical  co-morbities.    After 
presentation at a prospective multidis-
ciplinary tumor board, consensus rec-
ommendation  is  for  needle  localized 
wide  local excision and sentinel node 
biopsy  -  the  textbook  response.  Yet 
could there be a better approach?




through  what  sometimes  feels  like 
a  random  process  of  evolution,  and 






recognized  pioneer  in  breast  cancer 
therapy William Halsted, who devel-
oped  the first  standardized  approach; 
radical  resection  of  the  breast,  chest 
wall and nodal basins, it is easy to see 
how  far we have  come.    In Halsted’s 
era,  it  was  uncontrolled  local  disease 
that ravaged the patient and seemed to 
cause death. With the diagnosis of ear-




chemotherapy.  The  seminal  NSABP 




radical  resection.    Venturing  even 
further  into  therapeutic minimalism, 








recommendation.1    Since  that  time 
we  have  seen  a  progressive  decrease 
in  breast  cancer  size,  with  the  mean 
diameter  of  breast  cancer  decreasing 
by  10%  every  five  years.  For  Rhode 
Island, with the most successful state-





tion;  excision  guided  by  palpation  is 





nity  to  revolutionize  the  approach  to 
breast cancer surgery. 
Contemporary strategies
The  goals  of  breast  cancer  sur-
gery are to surgically remove the index 
cancer  from the body, eliminating  its 
potential  for  future  metastasis.  and 
to stage the axilla.  Subsequent radio-
therapy  completes  the  local  control. 
While  excising  the  cancer  is  way  to 
achieve  this  endpoint,  other  options 
are  numerous.   While more  contem-
porary modalities in‑situ ablation were 
not  available,  Hippocrates  described 
the  concept  of  thermal  destruction 
as  460  BC  and  in  the  first  century 
another  Greek  physician,  Leonides, 








Figure 1  A. Ultrasound demonstrating 
Cryoprobe placement within target 
lesion.
B.  Ultrasound during creation of iceball.  Note clear delin-
eation of treatment field.
creatIve clInIcIan case
FUTURE OF BREAST SURGERY
Jennifer S. Gass, MD, FACS
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in the understanding of thermal biol-
ogy and advances in both the delivery 




The  initial  reports  of  ablative 
techniques  in  breast  cancer  therapy 




fort  and  secondly  with  RFA  under 
ultrasound  guidance,  visualization  of 
the  treatment  zone  is  severely  com-
promised.    Although  other  modali-
ties  such  as  focused microwave,  laser 






are  identified  by  mammography  but 




of  breast  therapeutic  interventions  as 
well.    Furthermore,  during  cryoabla-
tion, frozen tissue becomes imminent-
ly  visible  under  ultrasound,  in  direct 
contradistinction  to  thermally heated 




Cryo  technology  has  advanced 
as  well. While  once  bulky,  unwieldy 
and  slow,  relying  on  liquid  nitrogen, 
the  new  device  includes  a  small  lap-
top sized consol and a 2.7 mm probe 
through  which  the  cooling  argon  is 
delivered.  (Figure  2) The  entire  pro-
cess  involves  a  freeze-thaw-freeze-
cycle that results in tissue destruction 
through  intra  cellular  ice  formation, 
causing  cellular wall  disruption,  sub-
sequent  osmotic  injury  and  delayed 
micro  vascular  disruption  leading  to 
tissue  ischemia. The  usual  treatment 










“image  occult”  disease,  specifically 
lobular and in situ carcinomas that do 
not reveal their full extent on imaging. 
Magnetic resonance imaging (Mri) 
has  emerged  as  the  premier  imaging 
modality  to  document  extent  of  dis-
ease in breast cancer.  To this end, the 
American College of Surgeons Oncol-
ogy Group  is  evaluating  the  sensitiv-








the  ice  ball  intra-operatively  to  allow 
for palpated  excision of  a non-palpa-
ble  cancer.   The  study  endpoints  are 
percent of patients achieving negative 
margin at index operation. Wthe final 
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Figure 2.  Tabletop cryoablation  system.
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Weight  gain  is  a  common  concern 
when  treating  patients  with  antidepres-
sant  medications.   The  actual  effects  of 
antidepressant medications on weight are 












fect of  tricyclic antidepressants (tCas) 
and  monoamine oxidase inhibitors 
(Maois).   The  antidepressant  action of 
MAOIs  results  from  the  irreversible  in-
hibition  of  two monoamine  oxidase  en-
zyme  isoforms,  MAO-A  and  MAO-B. 






weight  gain;  however,  this  conclusion  is 
based primarily on case reports.1 Another 




re-uptake  at  several  sites,  including  se-
rotonin,  adrenergic  and  histamine  re-
ceptors. The nonselective pharmacologic 







selective serotonin reuptake in-
hibitors (ssris) have a more selective and 
potent  effect  on  serotonin  than  the  less 
selective  activity  of TCAs. However,  the 
mechanism of antidepressant action is not 
entirely understood and  is due  to  effects 
other than the reuptake of serotonin at the 
neurosynapse.  4 An  increase  in  serotonin 
availabiliy  should  decrease  carbohydrate 
intake and reduce cravings,3 but this effect 
is unpredictable and poorly documented. 












obsessive-compulsive  disorder  were  ran-
domized to treatment with clomipramine, 
citalopram, fluoxetine,  fluvoxamine,  par-
oxetine or  sertraline  for 2.5 years.   Over 
the course of the trial, mean body weight 
increased  by  1.58  kg  (2.5%)  compared 
to baseline, with 14.5% of patients expe-




(4.86%)  and  the  highest  proportion  of 
















(0.2%)  among  fluoxetine  patients  and 
advances In Pharmacology
Antidespressant-induced Weight Gain
Sarah Grace Kachur, PharmD, Christine L. Hannan, PharmD, and Kristina E. Ward, PharmD
Treatment Group 
(daily dose range)
Mean Percen t -
age Change at 6 
Months*
Mean Percentage 





(150-250 mg) 0.89 4.86
† 34.8
Citalopram
(40-80 mg) 1.06 2.53
† 14.3
Fluoxetine
(40-80 mg) -0.40 0.92 8.7
Fluvoxamine
(200-300 mg) 1.14 2.61
† 10.7
Paroxetine
(40-80 mg) 1.43 2.59
† 14.3
Sertraline








habits caused by 
depression are 
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a  small mean  increase  in weight  (1.0%) 
among sertraline patients; neither change 
was  statistically  significant.    Paroxetine-
treated  patients  experienced  a  significant 
increase  in  weight  compared  with  base-
line (3.6%).  From baseline to endpoint, 
25.5%,  6.8%  and  4.2%  of  paroxetine, 
fluoxetine  and  sertraline patients,  respec-
tively,  experienced  7%  or  greater weight 
gain (P = 0.016 paroxetine vs fluoxetine, P 
= 0.003 paroxetine vs sertraline).  
When  fluoxetine  was  compared  to 
placebo for the prevention of relapse after 
acute  treatment of depression, fluoxetine 
was  associated  with  significantly  more 
weight gain than placebo over one year.7 




treatment  phase,  patients  were  random-
ized to 14, 26 or 38 weeks of continuation 
fluoxetine  therapy  or  placebo  for  relapse 



















the  long-term  treatment  phase  (16-44 
weeks),  fewer  nefazodone  than  SSRI 
patients experienced significant (≥ 7%) 
weight gain (8.3% vs. 17.9%, P = 0.003 
for  any  point  during  treatment  and 
6.9% vs. 13.8%, P = 0.007 at endpoint). 
There was no difference between groups 
in  the  incidence  of  significant  weight 
loss (≥ 7%) during long-term treatment. 
Fewer  instances  of  weight  loss  during 
the acute phase and weight gain during 
long-term  therapy  suggest  that  nefazo-
done causes less weight variability than 
SSRIs.
The  weight  gain  associated  with 
mirtazapine may  be  due  to  its  activity 
at histamine receptors.9  In a long-term 
continuation  of  a  trial  of  acute  treat-
ment,  patients  continued  treatment 
with mirtazapine, amitriptyline, or pla-
cebo for up to two years.10 Weight gain 
was  more  common  with  amitriptyline 
(22%) than mirtazapine (13%) patients, 
but significantly more mirtazapine than 
placebo  patients  experienced  weight 
gain.  In  a  four-week  study  of  healthy 
subjects,  those  treated  with  mirtazap-
ine  experienced  a  significant  increase 
in  body  weight  from  baseline  (mean 
increase  3.64  lb.),  suggesting  that  the 























of  treatment,  mirtazapine-treated  pa-
tients  experienced  a mean weight  gain 










the  agent  is most  likely  not  associated 
with significant weight gain or loss.
Bupropion  is  generally  associated 
with weight loss.  In an eight-week trial 
comparing  sustained  release  (SR)  bu-
propion  150-400 mg/day  to  sertraline 



















from  the  effects  of  depression,  the 
true  effects  of  SSRI  and  non-SSRI 
antidepressants  on  weight  have  yet  to 




paroxetine  is  associated  with  weight 
gain  early  in  therapy  but  the  long-
term  effects  are  unclear.  Fluoxetine 
may  cause  short-term  weight  loss  that 
resolves  with  continued  treatment. 
Other  SSRIs  are  either  weight-neutral 
or the effects have yet to be determined. 
Nefazodone appears  less  likely to cause 
weight  gain  than  SSRIs.  Bupropion  is 
often associated with weight  loss while 
mirtazapine  is  associated  with  weight 
gain  and  the  effects  of  venlafaxine 
remain unclear.
Several  factors  predict  the 
development  of  weight  gain  with 
antidepressants.   Combination  therapy 
with  multiple  antidepressants  or 
an  antidepressant  and  concomitant 
antipsychotic  may  increase  the  risk  of 
weight gain, but the adverse effects may 
counter  each  other  (e.g.,  bupropion 
and  an  SSRI).2    Patients with  appetite 
suppression  or  altered  eating  habits 
caused  by  depression  are  more  likely 
to  experience  weight  change  upon 




the  clinician  must  balance  the  risk 
of  weight  change  with  the  potential 
benefits of  treatment.  Slight increases 
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in weight upon initial treatment may 
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  Shakespeare’s  Romeo,  referring  to  the  lethal  potion 
that he is about to consume, exclaims: “O, true apothecary, 
Thy  drugs  are  quick.” The  old-fashioned  neighborhood 
drugstore has long since been superseded by national chains 
of markets  selling  all manner  of  health-related  products; 









word apothecary,  over  the  centuries, was modified  to  the 
Spanish  word,  bodega  (or  sometimes  bodetta) meaning  a 




 The  word  pharmacopeia,  a  registry  or  published 








or  love potions. The word  is  a modification of  the Greek 
philo‑, to love (as in words such as Anglophile or philoso-
phy.)
  The categories of medications  include  the  febrifuges, 
drugs  to fight  fever  (from the Latin  febris, meaning  fever, 
and fugo, meaning to flee); the anodynes, drugs to allay pain 
(the Greek privative prefix, ano- and dinos, meaning pain), 
the  emollients,  softening  agents  (Latin,  mollis,  meaning 
soft), the cathartics (from a Greek word meaning to cleanse, 
to  purify,  leading  to  such  English words  as  catharsis  and 
Cathartist),  the  emetics  (from  a Greek  word meaning  to 
vomit),  and  of  course,  the  aphrodisiacs,  named  to  honor 
Aphrodite, the Greek goddess of love (the Greek root, aph‑
ros, meaning  sea-foam,  is  a  reminder  that  Aphrodite  was 
said to have arisen from the foam of the sea.)
       Stanley M. Aronson, MD
The art and words of the apothecary
A Physician’s Lexicon
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  In  several  surveys  of  cervical 
cancer screening practices among ob-
stetricians  and  gynecologists  in  the 
United  States,  discrepancies  between 
published  guidelines  and  actual  pa-
tient management have emerged.  For 
example,  in  1998,  Suh-Burgmann 




College of obstetricians and Gyne-
cologists (aCoG)  or  the  national 
Cancer institute (nCi).1  As recently 
as 2005, Saint found that most gyne-
cologists  screen  low-risk  women  of-
ten  and  indefinitely  and  that  nearly 
three-quarters  would  begin  screening 
virginal  girls  at  age  18,  despite  na-
tional guidelines to the contrary.2 This 
review  summarizes recent recommen-
dations  for  cervical  cancer  screening 
and discusses  the  role of high-risk or 







er  prevalence  of  abnormal  screening 
Pap  smear  results  than adult  females, 




that  cervical  cancer  screening  should 
begin three years following the onset of 
vaginal  intercourse, but no  later  than 





recommended  that  routine  cytologic 
screening was unnecessary for women 
who  had  undergone  a  complete  hys-
terectomy for benign disease.4  Yet, in 
2002,  of  the  22  million  US  women 










to  stop  cervical  cancer  screening,6 
nearly half of women aged 65-74 are 
screened for cervical cancer annually.7
  Providers  continue  to  perform 
annual  screening  for  numerous 
reasons.   Noller19    speculated  that 
one  of  the major  reasons  driving  an-
nual  cervical  cytology  occurred  with 
the  introduction  of  oral contracep-
tives (oCps).  Physicians  linked  an-
nual screening to continuation of oral 
contraceptives,  thus  leading  to  the 
idea that every annual included a Pap 
smear.  Some may also adhere to older 
guidelines;  some  are  uncomfortable 




hpV typing in sCreening
  High-risk or oncogenic HPV is a 
necessary cause of nearly all high-grade 












in  this  population.    In  a  number  of 
studies,  combined HPV  testing  with 










cal  cytology  and HPV DNA  screen-
ing  in women aged 30 and over  ,14 a 
recommendation ACOG endorsed in 
2005.15    Today’s  commercial  probes, 
designed  to  identify  13  oncogenic 
HPV  subtypes,  are  sandwich  capture 
molecular  hybridization  assays  that 
utilize  chemiluminescent  detection. 
The  intensity  of  light  measured  is 
proportional  to  the  amount of  target 




HPV DNA  testing  as  an  adjunct  to 
cytology is expressly not recommend-
ed  for women under  30,  as  the high 












screening  in 3  years.    For  those with 
negative  HPV  typing,  but  abnormal 
cervical cytology, two situations arise. 
If the abnormality is ASC-US, repeat 
cytology  testing  is  recommended  in 
12 months.    For  any  other  cytologic 
abnormality,  colposcopy  is  recom-
mended.    On  the  other  hand,  if  a 
woman has ASC-US and  is  found to 
advances In laboratory medIcIne
HPV Testing and Cervical Cancer Screening: 
Recommendations and Practice Patterns
Lindsay M. Madom, MD, and Lori A. Boardman, MD, ScM
“… data suggest 
that combined 
testing with both 
cytology and 
high-risk HPV 











HPV  test.    Because  the  risk  of  CIN 
2  or  worse  is  low,  both  tests  should 
be  repeated  in 6  to 12 months.    For 
those with evidence of persistent HPV 
infection  but  negative  cytology,  col-
poscopy is warranted.14   Clearly, ques-




evidence  of  neoplasia  on  colposcopic 
examination.  At present, however, the 
rationale for treatment is unjustified. 
hpV typing in 




method  for ASC-US and as  a  test of 
cure for women following therapy for 
CIN  2  or CIN  3.15    Although HPV 
DNA  testing  was  not  found  to  be 
helpful  in  the management  of  LSIL, 
investigators  have  demonstrated  that 












HPV  testing  is  found  to  be  positive, 
the  patient  is  referred  to  colposcopy, 






  Finally,  in  a meta-analysis  of  11 
studies  evaluating  oncogenic  HPV 
typing  in monitoring women  treated 
for  CIN  3,  combined  testing  with 
high-risk  HPV  and  cytology  at  6 
months  following  therapy  proved 
more effective in predicting persistent 
CIN than either test alone or resection 







  In  summary,  guidelines  for  cer-
vical  cancer  screening  continue  to 
evolve, as knowledge of the pathogen-
esis  of  the  disease  as well  as  the  role 
of HPV  expands.     Oncogenic HPV 
typing  has  proven  effective  in  cancer 
screening  and  follow-up  in  certain 
situations,  and  its uses will undoubt-
edly  increase.   Patients  and providers 
may be reassured with negative HPV 






cer  screening will, we hope,    provide 
some of the answers regarding optimal 
management  of  women  who  remain 
persistently HPV positive.     
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Reducing  the proportion of Rhode 
Island  adults  who  are  obese  and  reduc-
ing the proportion of Rhode Island youth 
who are overweight and obese are healthy 





Island  girls  and women  on  overweight/
obesity, weight  control  strategies, physi-
cal activity, and fruit and vegetable con-
sumption  based  on  two  Rhode  Island 
surveys performed in 2003 -- the Behav-
ioral risk factor surveillance system 









for disease Control and prevention 
(CdC).3    In  2003,  RI’s  BRFSS  inter-
viewed 4,053 RI adults.
The  YRBS  is  an  anonymous  and 
voluntary  survey  conducted  in  alternate 
years  among  randomly  selected  high 
schools  and  students.   The CDC  spon-
sors  the  YRBS  in  states  and  localities 
nationwide.4  In  spring  2003  the Rhode 
Island  Departments  of  Education  and 
Health administered the YRBS to 1,814 
Rhode  Island  public  school  students  in 
grades 9 through 12.
In  2003  both  the  Rhode  Island 
BRFSS and YRBS collected information 
about height and weight, which are used 
to  calculate  body mass index (BMi); 







Are  you  eating  fewer  calories  or  less  fat 
to lose or maintain weight?  Are you ex-
ercising to lose or maintain weight?   In 




variables  for  physical  activity  and  one 
measure for fruit and vegetable consump-
tion.    For physical  activity  the  variables 
are: “meets guidelines  for recommended 
level  of  moderate  or  vigorous  physical 
activity” (30 minutes a day five or more 
days  a week,  or  20 minutes  or more  of 
vigorous physical activity 3 or more days 
a week); and “engages in no physical ac-
tivity.”    The  dietary  measure  is  “meets 
guidelines  for  fruit  and  vegetable  con-
sumption” (five or more servings of fruits 







of  adolescents who  are  at  risk  for  over-
weight  or  overweight,  to  32% of wom-
en  ages  18  –  24 who  are  overweight  or 
obese, up to 56% of women ages 65 and 
older.  While 21% of girls are at risk for 






percent  of  girls  and  nearly  half  of  all 
women are trying to  lose weight. (Table 







65  and  older  are  using  both  calorie  re-
striction  and physical  activity  to  lose  or 
maintain weight.   The proportion using 
dieting alone increases with age from 7% 




The  YRBS  also  asked  girls  about 
high  risks behaviors  to  lose or maintain 
weight; e.g.,  fasting for 24 hours or more 










Jana E. Hesser, PhD, and Donald K. Perry, MPA
Overweight and Weight Control among 
Rhode Island Girls and Women, 2003
Edited by Jay S. Buechner, PhD
Rhode Island Department of Health • David Gifford, MD, MPH, Director of Health
Health by Numbers

















At risk of overweight* 15%
Overweight** 21% 25% 31% 40% 30%
Overweight*** 6%
Obese**** 11% 18% 23% 16% 18%
Self–perceived overweight 35% NA NA NA NA NA
* At or above the 85th percentile but below the 95th percentile for BMI for age and sex based
  on data from the National Health and Nutrition Examination Survey I (NHANES I)5
** BMI >25 and <30
*** At or above the 95th percentile for BMI for age and sex based on NHANES I
**** BMI >30
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Girls  (60%)  and  women  ages  18 
– 24 (57%) have the highest proportion 




10%  of  girls  do  not  participate  in  any 







Addressing  the  epidemic  of  over-
weight  and  obesity  in  the  US  requires, 
in part, the individual intention to man-










Close  to  90%  of  girls  and women 
trying  to  lose  or  maintain  their  weight 
report doing so by restricting calories or 
fat, by exercising, or both.   While a high 
percentage  report  that  they  exercise  to 
control weight, a lower percentage report 
participation  in  the  recommended  level 
of  either moderate  or  vigorous  physical 
activity. A difference of about 20 percent-
age points between  the  two  estimates  is 
consistent across all age groups.
Likewise, the low proportion of girls 
and women  eating  the  recommended  5 
or more servings of fruits and vegetables 
is  discrepant  with  the  high  proportion 





ic.”    First,  the  discrepancy  between  the 
high level of weight management actions 
of  girls  and  women  and  their  reported 
physical  activity  and  fruit  and vegetable 
intake practices  suggests greater effort  is 
needed  to help  the public  recognize  the 
amount of exercise and types of food that 












be overweight,  efforts must  also  address 
when it is appropriate and healthy to en-
gage in weight loss strategies.
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Table 2.  Strategies and Objectives for Losing or Maintaining Weight among  High School Girls and 

















 Lose weight   61% 48% 49% 56% 40% 49%
 Maintain weight 19% 37% 38% 32% 35% 36%
Weight loss strategy (for those trying to lose or maintain weight):
 Just fewer calories/less fat 7% 13% 17% 26% 36% 23%
 Just exercise 23% 22% 16% 8% 9% 13%
 Both fewer calories and exercise 58% 52% 55% 58% 38% 52%
 Fasted 24 + hours 17% NA NA NA NA NA
 Took diet meds* 8% NA NA NA NA NA
 Vomited/took laxatives 6% NA NA NA NA NA
*Without doctor’s advice



















    Meet guidelines of 5 or more
    servings of fruits and vegetables per day 26% 26% 31% 30% 41% 32%
Physical Activity:
    Meet guidelines for recommended
    moderate or vigorous physical activity 60% 57% 55% 48% 28% 53%
    Does not participate in physical activity 10% 21% 25% 28% 40% 28%
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Rhode Island Department of Health Office of Women’s 
Health: A Gender Focus to Improve Health Status
Edited by John P. Fulton, PhD
Rhode Island Department of Health David Gifford, MD, MPH, Director of Health
Public Health Briefing
Nancy Libby-Fisher, MMHS
The  concept  of  women’s  health, 
traditionally,  has  focused  on  repro-
ductive health  and breast  and  cervical 
cancer.   This view has changed  in  the 
last decade to encompass the physical, 
mental,  social,  and  economic  factors 
that  influence  women’s  health  status 
across their lifespan.  
Women’s  health  is  devoted  to  fa-
cilitating  the  preservation  of  wellness 
and the prevention of illness in women 
and includes screening, diagnosis, and 
management  of  conditions  which  are 
unique  to women;  are more  common 
in women; are more serious in women; 
and  have  manifestations,  risk  factors 
or interventions which are different in 
women.1
health status of rhode 
island Women
The Office of Women’s Health was 
created  in  2001  to  provide  a  gender-
informed  approach  to  programs  and 




Health  disparities  for  Rhode  Is-
land women are not  solely  a  factor of 
gender.    In  addition  to  gender  differ-
ences  in  health  status,  there  are  also 
substantial differences between women 




Tobacco  use  in  Rhode  Island 




students.    A  higher  proportion  of  fe-
male  students  smoke  than  male  stu-
dents, with  the  greatest  difference  oc-
curring in the 9th grade.2  
Rhode  Island  women  self-report 
a  higher  rate  (11%)  of  asthma  than 
Rhode  Island men (6%), and  the  rate 
for RI women  is higher  than  the me-
dian for US women (9%).3
Physical activity decreases as wom-
en  age.    Regular  physical  activity  has 
been shown to reduce the risk of death 
from  heart  disease,  lower  the  risk  of 
developing diabetes, help prevent high 
blood pressures, and is associated with 
a  decreased  risk  of  colon  cancer.    Yet 
fewer than one woman in four (at any 
age) gets the minimum recommended 
amount  of  physical  activity  and  the 





nority  women  are  disproportionately 
affected.    State  data    show  that more 
than  half  of  all  Rhode  Island women 
are overweight or obese. Hispanic and 
Black  non-Hispanic  women  are more 
likely  to  be  overweight  than  White 
non-Hispanic  women,  and  minority 
women are more than twice as likely to 
be obese. 5
offiCe of Women’s health
The  health  status  of  men  and 
women differ in many areas.  Gender-
neutral  policies  assume  that  everyone 
is  affected  by  programs  in  the  same 
way.  The same interventions, however, 
do  not  necessarily  yield  equal  results; 





Among  its  responsibilities,  the 
Office  hosts  an  annual  statewide 
conference  on  women’s  health.    Past 
conferences  have  focused  on  women 
65  years  of  age  and  older,  women  in 
midlife from 45 – 64 years of age, and 
women of reproductive age between 18 
–  44  years.   This  year  the  conference 
will  focus on  adolescent  girls  aged 11 

























primarily  a  policy  office,  but  it  does 
have overall  responsibility  for  the De-
partment’s  Osteoporosis  Program.  In 
Rhode Island, the prevalence of osteo-












with  their  doctor  about  this  disease. 





the  number  of  undiagnosed  cases  of 
osteoporosis  and  increase  treatment. 
Professional  education  efforts  include 
articles  about  osteoporosis  in  Medi‑





The  Osteoporosis  Program  rou-
tinely assesses  the status of osteoporo-
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sis  in  Rhode  Island  by  means  of  the 
state’s  annual  Behavioral  Risk  Factor 
Surveillance  System  (BRFSS),    a  ran-
dom telephone health survey of Rhode 
Island  adults.    Some  of  the  questions 
ask  about  the  information  these  indi-





























on policies  and programs  that  impact 












who  live  in  poverty  or  have  less  than 
a  high  school  education  have  shorter 
life spans, higher rates of illness, injury, 
disability  and  death,  and  more  lim-
ited  access  to high quality health  care 
services.    There  is  a  high  correlation 
between  lower  literacy  levels,  poverty 
and  poorer  health  status. This  creates 
an  even  greater  burden  since women, 




1.  National  Academy  on  Women’s  Health 
Medical Education.
2.  Health  Policy  Brief  ,  RI  Department  of 
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Recent data from the 2004 national Behavioral risk 
factor surveillance survey (Brfss), a population-based 
telephone  survey  conducted by  the Centers for disease 





highest  percentage  of  women  40+  obtaining  screening 
mammograms is a tremendous accomplishment for Rhode 
Island.  Clearly,  the  Rhode  Island  medical  and  public 
health  communities  are  doing  a  great  job  at  promoting 
mammography screening. 
These self-reported data contrast sharply with the rates 
seen  when  examining  actual  claims  for  mammography. 
(Figure 1)  As part of its work as the Quality Improvement 





Of  the  8,686  female Medicare  beneficiaries  aged  50-69, 







underestimate  the  number  of  mammography  screenings 
through  a  combination of  lost  claims,  self-pay  or  use  of 
alternate  payers,  and  free  programs.2,3,4  One  study  in 
Colorado found that Medicare claims data underestimated 
true  screenings  by  15%.4  With  Rhode  Island  claims 
rates at only around 60%, one might assume that a true 
mammography  screening  rate  for  this  population hovers 
somewhere  around  75%,  indicating  that  one  in  four 
women in this high-risk group is not seeking or receiving a 
screening mammography.
In  contrast,  there  is  some  suggestion  that  BRFSS 






pertain  to  a particular  time period,  as women may  state 
that  a  mammogram  has  occurred  in  the  last  two  years 
when in fact it occurred outside of that time frame.5  While 
Medicare  claims  may  under-report  the  actual  screening 
rate, and BRFSS possibly over  reports  that  rate, one can 
conclude  that  there  is  still  a  substantial  portion  of  the 
Medicare population in Rhode Island, somewhere between 
15-25%, who  are not  receiving  the  appropriate  screening 
for breast cancer.  
According  to  claims  data Rhode  Island  has  achieved 
little  success  in  increasing  the  percentage  of  women  on 
Medicare who obtain screening mammograms since 1991-
2004,  despite the fact that mammograms are fully covered 
by Medicare.    National  claims-based  rates  also  declined, 
from    59.7%  to  59.1%  in  the  same  period.  Intensive 
interventions targeting this age group in Rhode Island have 
yielded  little  improvement.  A  three-year,  multi-pronged 








with  advanced  breast  cancer  at  diagnosis  than  younger 
women.6,7  Screening  mammography  has  been  shown  to 
reduce mortality from breast cancer by 20% to 39% among 
women  aged  50  and  older.8    Rhode  Island  women  on 





Are Older Rhode Island Women Receiving 
Appropriate Screening for Breast Cancer?
Johanna Bell Butler,  MPH, Maureen Claflin,   RN, MSN, Deidre S. Gifford, MD, MPH
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has  been  ordered  to  be  sure  that  it  has  occurred.   With 




facilities  found  that  screening  appointment  wait  times 
ranged from 1 day to 150 days, with few facilities sending 
reminder  cards  or  letters  to  women  who  are  due  for  a 
mammogram.  Women  referred  by  their  doctors  to  a 
specific facility, and discovering a wait time of several weeks 
or months, may be failing to make an appointment or keep 
the  appointment  that  is  scheduled  too  far  in  advance. 









Women  on  Medicare  may  face  unique  challenges 
that  impact  on  their  likelihood  to  seek  screening 
mammograms.  Some women  still  are  not  aware  of  their 
need to be screened.12 Women under age 65 on Medicare 
face  co-existing  morbidities  that  qualify  them  for  the 
program  at  a  younger  age. These  health  conditions may 
limit their independence and/or mobility. Additionally, the 
day-to-day demands of managing competing morbidities, 
including  physician  visits,  treatments,  medications,  and 
tests,  can  push  preventive  screenings  into  low  priority 
and even cause patients to question the utility of “looking 











to  undergo  treatment  in  determining  whether  to  refer 
female patients over 70 for mammography screenings.13
The  Rhode  Island  medical  and  public  health 
community  has  a  proud  record  of  promoting  and 
facilitating  annual mammography  screenings  for  women 
over  40.  Yet  the  data  continue  to  point  to  a  significant 
proportion of those on Medicare who have not shared in 
the  improved mammography  screening  rates  despite  full 
coverage  for mammography  screening  and  increased  risk 
for  breast  cancer.    Special  attention must  be  paid  to  the 
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The analyses upon which this publication is based were per-
formed under Contract Number 500-02-RI02, funded by the 
Centers for Medicare & Medicaid Services, an agency of the 
U.S. Department of Health and Human Services. The content of 
this publication does not necessarily reflect the views or poli-
cies of the Department of Health and Human Services, nor does 
mention of trade names, commercial products, or organizations 
imply endorsement by the U.S. Government. The author assumes 
full responsibility for the accuracy and completeness of the ideas 
presented.
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(a) Cause of death statistics were derived from the 
underlying cause of death reported by physicians on 
death certificates.
(b) Rates per 100,000 estimated population of 
1,069,725
(c) Years of Potential Life Lost (YPLL)
Note: Totals represent vital events which occurred in Rhode Island 
for the reporting periods listed above. Monthly provisional totals 
should be analyzed with caution because the numbers may be 
small and subject to seasonal variation.
Rhode Island Monthly 
Vital Statistics Report
Provisional Occurrence Data 
from the 
Division of Vital Records
Edited by Roberta A. Chevoya, State Registrar
Rhode Island Department of Health
David Gifford, MD, MPH, 
Director of Health
 Number (a) Number (a) Rates (b) YPLL (c)
Diseases of the Heart 221 2,989 279.4 4,574.0
Malignant Neoplasms 222 2,479 231.7 6,919.0
Cerebrovascular Diseases 39 491 45.9 822.5
Injuries (Accident/Suicide/Homicide) 45 459 42.9 7,119.5
COPD 31 461 43.1 372.5
Reporting PeriodUnderlying 
Cause of Death 12 Months Ending with October 2004
 Number Number Rates
Live Births 1350 13,533 12.7*
Deaths 824 10,181 9.5*
 Infant Deaths (10) (84) 6.2#
  Neonatal deaths (8) (68) 5.0#
Marriages 463 8,069 7.5*
Divorces 207 3,176 3.0*
Induced Terminations 455 5,437 401.8#
Spontaneous Fetal Deaths 84 1,016 75.1#
 Under 20 weeks gestation (76) (933) 68.9#





* Rates per 1,000 estimated population # Rates per 1,000 live births
** Excludes one death of unknown age.













pride  a  silver  loving  cup,  a  gold watch…but  these  instances  are 
now so rare that they are to be regarded as a curiosity of medical 
life and not an essential part of it.”
  W.H.  Peters,  MD,  discussed  “Carelessness  in  Physical 
Examinations  for  Life  Insurance.” Dr.  Peters  confessed:  “I  have 
witnessed  life  insurance  examinations  for  good-sized  policies 







fifty years ago, oCtoBer 1955
  Stewart  Armstrong,  MD,  Instructor  in  Surgery,  Boston 
University  School  of Medicine,  contributed  “Segmental  Arterial 
Occlusions Treated  with  Resection  and  Grafting.”  Of  ten  cases 
discussed,  6  had  a  “good  result”  [“preservation  of  the  already 
doomed extremity”], 4 were failures [”loss 
of limb”]. 
  Herbert  Fanger,  MD,  in  “Long 
Term  Survival  in  Cancer  of  Breast, 
Stomach and in Malignant Melanomas,” 
traced 5 year survival over distinct spans. 
From 1932-35,  of  142  cases,  14%  lived 
at least 5 years. The survival rate peaked in 1941-45: of 160 cases, 
31% met  the 5-year goal. By 1946-48,  the  rate had dropped  to 
25% (98 cases). 
  Seebert Goldowsky, MD,  continued with  “The Beginnings 
of Medical Education in Rhode Island, Part 11.” In 1822 Brown 
launched  a  medical  program,  paying  faculty  stipends  for  part-
time  lecturing  ($10-15  for  a  3-month,  once-a-month  lecture 
series).  Rev.  Francis  Wayland,  Jr,  who  became  president  in 
1828,  effectively  ended  the  medical  program  by  abolishing  the 
faculty  positions.  President  Wayland  replaced  Asa  Messer;  and 
the  corporation  charged  this  new  president  with  improving  the 
University.  Dr.  Goldowsky  analyzed  the  decision  to  bar  off-site 
faculty as “incidental” to strengthening the University, not part of 
an express intent to end the medical curriculum.  
tWenty-fiVe years ago, oCtoBer 1980
  Guy  A.  Settipane,  MD,  discussed  “Anaphylactic  Reactions 
in  Asthmatic  Patients.”  The  “likelihood  of  significant  reactions 
depend upon the specific immunological mechanisms involved.”  
  Eugene  G.  Laforet,  MD  [Chief  of  Thoracic  Surgery, 
Newton-Wellesley Hospital], and Robert L. Berger, MD [Chief of 
Cardiothoracic Surgery, University Hospitals, Boston), contributed 
“The  Use  of  the  Celestin  Tube  in  Complicated  Esophageal 
Problems.” They asserted: “The device may be palliative or curative 
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